0001255294-11-000487.txt : 20110816 0001255294-11-000487.hdr.sgml : 20110816 20110816115802 ACCESSION NUMBER: 0001255294-11-000487 CONFORMED SUBMISSION TYPE: 10-Q/A PUBLIC DOCUMENT COUNT: 10 CONFORMED PERIOD OF REPORT: 20110630 FILED AS OF DATE: 20110816 DATE AS OF CHANGE: 20110816 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Regenicin, Inc. CENTRAL INDEX KEY: 0001412659 STANDARD INDUSTRIAL CLASSIFICATION: INDUSTRIAL & COMMERCIAL FANS & BLOWERS & AIR PURIFYING EQUIP [3564] IRS NUMBER: 000000000 STATE OF INCORPORATION: NV FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 10-Q/A SEC ACT: 1934 Act SEC FILE NUMBER: 333-146834 FILM NUMBER: 111039237 BUSINESS ADDRESS: STREET 1: 10 HIGH COURT CITY: LITTLE FALLS STATE: NJ ZIP: 07424 BUSINESS PHONE: 646-403-3581 MAIL ADDRESS: STREET 1: 10 HIGH COURT CITY: LITTLE FALLS STATE: NJ ZIP: 07424 FORMER COMPANY: FORMER CONFORMED NAME: Windstar Inc. DATE OF NAME CHANGE: 20070918 10-Q/A 1 mainbody.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-Q /A

Amendment No. 1

 

[X] Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
For the quarterly period ended June 30, 2011
[   ] Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934
For the transition period from __________ to__________
Commission File Number: 333-146834

 

Regenicin, Inc.

(Exact name of registrant as specified in its charter)

 

NV 27-3083341
(State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.)

 

10 High Court, Little Falls, NJ
(Address of principal executive offices)

 

(646) 403-3581
(Registrant’s telephone number)

 

___________________________

(Former name, former address and former fiscal year, if changed since last report)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days [ ] Yes [ ] No

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). [ ] Yes [ ] No

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.

 

[ ] Large accelerated filer [ ] Accelerated filer
[ ] Non-accelerated filer [X] Smaller reporting company

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). [X ] Yes [ ] No

 

State the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 88,236,324 as of April 30, 2011.

 

 
 

EXPLANATORY NOTE

This Amendment No. 1 to the Quarterly Report on Form 10-Q/A (the “Amendment”) amends the Quarterly Report on Form 10-Q of Regenicin, Inc. (the “Company”) for the quarter ended June 30, 2011 (the “Original Filing”), that was originally filed with the U.S. Securities and Exchange Commission on August 15, 2011. The Amendment is being filed to submit Exhibit 101. The Amendment revises the exhibit index included in Part II, Item 6 of the Original Filing and includes Exhibit 101 (XBRL interactive data) as an exhibit to the Amendment.

Except as described above, the Amendment does not modify or update the disclosures presented in, or exhibits to, the Original Filing in any way. Those sections of the Original Filing that are unaffected by the Amendment are not included herein. The Amendment continues to speak as of the date of the Original Filing. Furthermore, the Amendment does not reflect events occurring after the filing of the Original Filing. Accordingly, the Amendment should be read in conjunction with the Original Filing, as well as the Company’s other filings made with the SEC pursuant to Section 13(a) or 15(d) of the Exchange Act subsequent to the filing of the Original Filing.

 
 

PART II – OTHER INFORMATION

 

Item 6. Exhibits

 

Exhibit Number Description of Exhibit
31.1 Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2 Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1 Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101** The following materials from the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2011 formatted in Extensible Business Reporting Language (XBRL).

**Provided herewith

 
 

SIGNATURES

 

In accordance with the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Regenicin, Inc.
Date: August 16 , 2011
   
By: /s/ Randall McCoy
  Randall McCoy
Title: Chief Executive Officer and Director

 

 EX-31.1 2 ex31_1.htm EXHIBIT 31.1

CERTIFICATIONS

 

I, Randall McCoy, certify that;

 

1. I have reviewed this amended quarterly report on Form 10-Q/A for the quarter ended June 30, 2011 of Regenicin, Inc. (the “registrant”);

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: August 16 , 2011
 
  /s/Randall McCoy
By: Randall McCoy
Title: Chief Executive Officer

 

 
 

 

 EX-31.2 3 ex31_2.htm EXHIBIT 31.2

CERTIFICATIONS

 

I, Randall McCoy, certify that;

 

1. I have reviewed this amended quarterly report on Form 10-Q/A for the quarter ended June 30, 2011 of Regenicin, Inc. (the “registrant”);

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: August 16 , 2011
 
  /s/Randall McCoy
By: Randall McCoy
Title: Chief Financial Officer

 

 
 

 

 EX-32.1 4 ex32_1.htm EXHIBIT 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND

CHIEF FINANCIAL OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

 

In connection with the amended quarterly Report of Regenicin, Inc. (the “Company”) on Form 10-Q/A for the quarter ended June 30, 2011 filed with the Securities and Exchange Commission (the “Report”), I, Randall McCoy, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

1.             The Report fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934; and

 

2.             The information contained in the Report fairly presents, in all material respects, the consolidated financial condition of the Company as of the dates presented and the consolidated result of operations of the Company for the periods presented.

 

By: /s/ Randall McCoy
Name: Randall McCoy
Title:

Principal Executive Officer,

Principal Financial Officer and Director

Date: August 16 , 2011

 

This certification has been furnished solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

 
 

 

 EX-101.INS 5 rgin-20110530.xml XBRL INSTANCE FILE 0001412659 2011-08-01 0001412659 2011-06-30 0001412659 2010-10-01 2011-06-30 0001412659 2009-10-01 2010-06-30 0001412659 2007-09-06 2011-06-30 0001412659 2011-04-01 2011-06-30 0001412659 2010-04-01 2010-06-30 0001412659 2010-09-30 0001412659 2009-09-30 0001412659 2010-06-30 0001412659 2007-09-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares Regenicin, Inc. 0001412659 10-Q 2011-06-30 true --09-30 No No Yes Smaller Reporting Company 2011 83807965 118988 25970 170076 30534 3007500 3007500 3177576 3038034 655208 221762 354077 138985 10000 150000 2000 318789 1021285 829536 1021285 829536 88237 86407 7565596 3116841 4428 2156291 2208498 3177576 3038034 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 1 - THE COMPANY</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Windstar, Inc. (the &#147;Company&#148;) was incorporated in the state of Nevada on September 6, 2007 and is in the development stage. On July 19, 2010, the Company amended its Articles of Incorporation to change the name of the Company to Regenicin, Inc.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#146;s original business was the development of a purification device.&#160;&#160;Such business was assigned to the Company&#146;s former management in July 2010.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#160;&#160;has adopted a new business plan and intends to help develop and commercialize a potentially lifesaving technology by the introduction of tissue-engineered skin substitutes to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds and a variety of plastic surgery procedures. To this end, we have entered into an agreement with Lonza Walkersville, Inc. (&#147;Lonza&#148;) for the exclusive license to use certain proprietary know-how and information necessary to develop and seek approval by the U.S. Food and Drug Administration (&#147;FDA&#148;) for the commercial sale of a product known as PermaDerm&#153;.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">PermaDerm&#153; is a tissue-engineered skin substitute prepared from autologous (patient&#146;s own) skin cells. It is a combination of cultured epithelium with a collagen-fibroblast implant that produces a skin substitute that contains both epidermal and dermal components. This model has been shown in preclinical studies to generate a functional skin barrier and in clinical studies to promote closure and healing of burns. Critically, the Company believes that self-to-self skin grafts for permanent skin tissue will not be rejected by the immune system of the patient, unlike with porcine or cadaver grafts in which rejection is an important possibility.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 2 - BASIS OF PRESENTATION</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying unaudited financial statements of Regenicin, Inc. (the &#147;Company&#148;) have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and with Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the nine months ended June 30, 2011 are not necessarily indicative of the results that may be expected for the year ending September 30, 2011. These unaudited financial statements should be read in conjunction with the audited financial statements and footnotes thereto included in the Company's Annual Report on Form 10-K for the year ended September 30, 2010, as filed with the Securities and Exchange Commission.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Going Concern:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#146;s financial statements have been prepared assuming that the Company will continue as a going concern which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company has incurred cumulative losses of approximately $5.5 million for the period September 6, 2007 (inception date) through June 30, 2011, expects to incur further losses in the development of its business and has been dependent on funding operations through the issuance of convertible debt and private sale of equity securities. These conditions raise substantial doubt about the Company&#146;s ability to continue as a going concern. Management&#146;s plans include continuing to finance operations through the private or public placement of debt and/or equity securities and the reduction of expenditures. However, no assurance can be given at this time as to whether the Company will be able to achieve these objectives. The financial statements do not include any adjustment relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Development Stage Activities and Operations:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is in the development stage and has had no revenues.&#160;&#160;A development stage company is defined as one in which all efforts are devoted substantially to establishing a new business and even if planned principal operations have commenced, revenues are insignificant.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 3 - LOSS PER SHARE</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted loss per share give effect to dilutive convertible securities, options, warrants and other potential common stock outstanding during the period, only in periods in which such effect is dilutive. The following securities have been excluded from the calculation of net loss per share, as their effect would be anti-dilutive:</p> <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"> <tr> <td style="width: 100%; font: 12pt/115% Times New Roman, Times, Serif; padding-right: 0.8pt"></td></tr> </table> <p style="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" align="center" style="width: 50%; font: 11pt Times New Roman, Times, Serif; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="padding-right: 0.8pt; line-height: 115%; text-align: center"></td> <td colspan="7" style="padding-right: 6.8pt; line-height: 115%; text-align: center"> <font style="font: 10pt Times New Roman, Times, Serif">Shares of Common Stock</font></td></tr> <tr style="vertical-align: bottom"> <td style="padding-right: 0.8pt; line-height: 115%; text-align: center"></td> <td colspan="7" style="padding-right: 6.8pt; line-height: 115%; text-align: center"> <font style="font: 10pt Times New Roman, Times, Serif">Issuable upon Conversion/Exercise</font></td></tr> <tr style="vertical-align: bottom"> <td style="padding-right: 0.8pt; line-height: 115%; text-align: center"></td> <td colspan="7" style="border-bottom: black 1pt solid; padding-right: 6.8pt; line-height: 115%; text-align: center"> <font style="font: 10pt Times New Roman, Times, Serif">as of June 30,</font></td></tr> <tr style="vertical-align: bottom"> <td style="padding-right: 0.8pt; line-height: 115%; text-align: center"></td> <td colspan="3" style="border-bottom: black 1pt solid; padding-right: 2.8pt; line-height: 115%; text-align: center"> <font style="font: 10pt Times New Roman, Times, Serif">2011</font></td> <td style="padding-right: 0.8pt; line-height: 115%"></td> <td colspan="3" style="border-bottom: black 1pt solid; padding-right: 2.8pt; line-height: 115%; text-align: center"> <font style="font: 10pt Times New Roman, Times, Serif">2010</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,204)"> <td style="width: 54%; padding-right: 0.8pt; line-height: 115%"> <font style="font: 10pt Times New Roman, Times, Serif">Options</font></td> <td style="width: 2%; padding-right: 0.8pt; line-height: 115%"></td> <td style="width: 19%; padding-right: 0.8pt; line-height: 115%; text-align: right"> <font style="font: 10pt Times New Roman, Times, Serif">5,542,688</font></td> <td style="width: 2%; padding-right: 0.8pt; line-height: 115%"></td> <td style="width: 2%; padding-right: 0.8pt; line-height: 115%"></td> <td style="width: 2%; padding-right: 0.8pt; line-height: 115%"></td> <td style="width: 17%; padding-right: 0.8pt; line-height: 115%; text-align: right"> <font style="font: 10pt Times New Roman, Times, Serif">-0-</font></td> <td style="width: 2%; padding-right: 0.8pt; line-height: 115%; font-size: 12pt"></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-right: 0.8pt; line-height: 115%"> <font style="font: 10pt Times New Roman, Times, Serif">Warrants</font></td> <td style="padding-right: 0.8pt; line-height: 115%"></td> <td style="padding-right: 0.8pt; line-height: 115%; text-align: right"> <font style="font: 10pt Times New Roman, Times, Serif">2,300,067</font></td> <td style="padding-right: 0.8pt; line-height: 115%; font-size: 12pt"></td> <td style="padding-right: 0.8pt; line-height: 115%"></td> <td style="padding-right: 0.8pt; line-height: 115%"></td> <td style="padding-right: 0.8pt; line-height: 115%; text-align: right"> <font style="font: 10pt Times New Roman, Times, Serif">-0-</font></td> <td style="padding-right: 0.8pt; line-height: 115%; font-size: 12pt"></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,204)"> <td style="padding-right: 0.8pt; line-height: 115%; font-size: 10pt">Convertible Preferred Stock</td> <td style="padding-right: 0.8pt; line-height: 115%; font-size: 10pt"></td> <td style="padding-right: 0.8pt; line-height: 115%; font-size: 10pt; text-align: right">13,300,000</td> <td style="padding-right: 0.8pt; line-height: 115%; font-size: 10pt"></td> <td style="padding-right: 0.8pt; line-height: 115%; font-size: 10pt"></td> <td style="padding-right: 0.8pt; line-height: 115%; font-size: 10pt"></td> <td style="padding-right: 0.8pt; line-height: 115%; font-size: 10pt; text-align: right">-0-</td> <td style="padding-right: 0.8pt; line-height: 115%; font-size: 12pt"></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 4 - INTANGIBLES ASSETS</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In July 2010, the Company entered into an agreement with Lonza for the exclusive license to use certain proprietary know-how and information necessary to develop and seek approval by the U.S. Food and Drug Administration (&#147;FDA&#148;) for the commercial sale of a product known as PermaDerm&#153;.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company paid Lonza $3,000,000 for the exclusive know-how license and assistance to seek approval from the FDA for the commercial sale of PermaDerm&#153; in the U.S., and later for approval in foreign jurisdictions for commercial sale of PermaDerm&#153; throughout the world. In conjunction with Lonza, we intend to create and implement a strategy to conduct human clinical trials and to assemble and present the relevant information and data in order to obtain the necessary approvals for PermaDerm&#153; and possible related products.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In August 2010, the Company paid $7,500 and obtained the rights to the trademarks PermaDerm&#174; and TempaDerm&#174; from KJR-10 Corp.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Intangible assets, which include purchased licenses, patents and patent rights, are stated at cost and will be amortized using the straight-line method over their useful lives based upon the pattern in which the expected benefits will be realized, or on a straight-line basis, whichever is greater.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We review our intangible assets subject to amortization whenever events or changes in circumstances indicate that the carrying amount of such an asset may not be recoverable. Recoverability of these assets is measured by comparison of their carrying amount to the future undiscounted cash flows the assets are expected to generate. If such assets are considered impaired, the impairment to be recognized is equal to the amount by which the carrying value of the assets exceeds their fair value determined by either a quoted market price, if any, or a value determined by utilizing a discounted cash flow technique. In assessing recoverability, we must make assumptions regarding estimated future cash flows and discount factors. If these estimates or related assumptions change in the future, we may be required to record impairment charges. We did not record any impairment charges in the nine months ended June 30, 2011.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 6 &#150; NOTE PAYABLE</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On August 2, 2010, the Company issued a $150,000 demand promissory note (the &#147;Demand Note&#148;) to NPNC Management, LLC (&#147;NPNC&#148;), a company whose principals also represent the Company as securities counsel.&#160;&#160;The Demand Note bore interest at 5% per annum.&#160;&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In March 2011, the Company executed a Promissory Note and Security Agreement (the &#147;Note&#148;) with NPNC and three of the Company&#146;s directors, Craig Eagle, Joseph Rubinfeld, and John Weber for $265,000. Mr. Eagle, Mr. Rubinfeld, and Mr. Weber contributed $80,000 and NPNC agreed to contribute the remaining $185,000 of the loan of which $150,.000 was previously borrowed and represented by the existing Demand Note and the balance of $35,000 in new funding.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Note accrued interest at 5% per annum. The Note, together with all accrued interest, was due and payable by June 14, 2011. In June 2011, the Note was repaid with interest from the proceeds of the Preferred Stock Offering.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 7 &#150; RELATED PARTY TRANSACTIONS</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>The Broadsmoore Group, LLC (&#147;TBG&#148;):</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">TBG is a stockholder of the Company.&#160;&#160;On August 30, 2010, the Company had entered into a finance representation agreement with TBG.&#160;&#160;TBG was to provide advice to the Company and evaluate relevant transactions the Company may consider.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, TBG advanced monies to the Company.&#160;&#160;The advances were due on demand and were non-interest bearing.&#160;&#160;In addition, the Company was utilizing the office space and employees of TBG at no cost.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the nine and three months ended June 30, 2011 and 2010, the Company did not incur any fees to TBG.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify">In fiscal 2011, the Company borrowed additional funds from TBG.&#160;&#160;Effective December 30, 2010, the Company and TBG signed a settlement agreement by which TBG accepted 666,667 shares of common stock in exchange for all monies owed TBG to date (approximately $506,000).&#160;&#160;These shares were previously issued as part of the October 28, 2010 offering.&#160;&#160;In addition, the Company orally agreed to pay a $200,000 success fee to TBG if the Company raises the remaining $3.5 million being offered in its current offering that commenced on October 28, 2010 (see Note 8 &#150; Stockholders&#146; Equity).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 8 &#150; STOCKHOLDERS&#146; EQUITY</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Authorized Shares:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On October 27, 2010, the Company increased the number of authorized shares of common stock from 90,000,000 shares to 200,000,000 by amending our Articles of Incorporation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Series A Convertible Preferred Stock:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In June 2011, the Company issued 1,330,000 shares of newly designated Series A Convertible Preferred Stock (&#147;Series A Preferred&#148;) and 665,000 Warrants in a private placement, The gross purchase price of the units sold was $1,330,000 of which $105,000 was from loans from certain investors that were converted and $60,000 of cash advances from TBG for the payment of certain operating expenses. In July 2011, the Company issued an additional 15,000 Series A convertible preferred stock and 7,500 Warrants.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company has accounted for the value of the Warrants in accordance with ASC Topic 470, whereby the Company separately measured the fair value of the Series A Preferred and the Warrant and allocated the total proceeds in accordance with their relative fair value at the time of issuance. The Company valued the warrant at $50,078 utilizing a Black-Scholes option pricing model with the following assumptions:&#160;&#160;share price: $0.21; exercise price: $0.15; expected volatility: 26.22%; risk-free rate: .66%; expected term: 3.5 years. The value of the Warrants was recorded as a deemed dividend.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The expected life is the number of years that the Company estimates, based upon history, that the Warrants will be outstanding prior to exercise or forfeiture. Expected life is determined using the &#147;simplified method&#148; permitted by Staff Accounting Bulletin&#160;No. 107. The stock volatility factor is based on the Nasdaq Biotechnology Index. The Company did not use the volatility rate for Company Common Stock as the Company Common Stock had not been trading for the sufficient length of time to accurately compute its volatility when these options were issued.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In addition, in accordance with the provisions of ASC Topic 470, the Company allocated a portion of the proceeds received to the beneficial conversion feature, based on the difference between the effective conversion price of the proceeds allocated to the Series A Preferred and the fair value of the underlying common stock on the date the convertible preferred stock was issued. The discount resulting from the beneficial conversion feature was recorded as a deemed dividend in the amount of $1,279,922.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Series A Preferred pay a dividend of 8% per annum on the stated value and the holders do not vote separately as a class (but do vote on an &#147;as-converted&#148; to common stock basis) and have a liquidation preference equal to the stated value of the shares. Each share of Preferred Stock has an initial stated value of $1 and is convertible into shares of the Company&#146;s common stock at the rate of 10 for 1. The dividends are cumulative commencing on the issue date whether or not declared.&#160;&#160;For both the nine and three months ended June 30, 2011, dividends totaled $2,444.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For both the nine and three months ended June 30, 2011, dividends and deemed dividends totaled $1,332,444. At June 30, 2011, dividends payable total $2,444 and are included in accrued expenses.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Common Stock Issuances:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Private Placement</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On October 28, 2010, the Company began offering under a Private Placement Memorandum up to 6,000,000 shares of its common stock at an offering price of $0.75 per share.&#160;&#160;Offering expenses are estimated to be equal to 10% of the offering price.&#160;&#160;For the period October 28, 2010 through February 10, 2011, the Company sold 623,400 shares of common stock and received gross proceeds of $467,550.&#160;&#160;Expenses related to the offering totaled $75,777 and were offset against additional paid-in capital.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>TBG</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Effective December 30, 2010, TBG accepted 666,667 shares of common stock in exchange for all monies owed TBG to date (approximately $506,000).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Services Rendered</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On November 22, 2010, the Company issued 150,000 shares for consulting services rendered.&#160;&#160;The shares were valued at $112,500.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In February and March 2011, the Company issued 390,000 shares for consulting services rendered.&#160;&#160;The shares were valued at $247,975.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Stock compensation expense related to the shares totaled $360,475 and $247,975 for the nine and three months ended June 30, 2011, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Treasury Stock:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 19, 2010, Mr. McCoy agreed to deliver to the Company 4,428,360 shares of common stock beneficially owned by him with instructions that such shares be cancelled and returned to treasury.&#160;&#160;Such shares were to be returned to offset the potential dilution caused by an equity incentive plan for directors involving the same number of shares that was adopted (see below). Mr. McCoy delivered the shares on January 5, 2011.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>2010 Incentive Plan:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On December 15, 2010, the board of directors approved the Regenicin, Inc. 2010 Incentive Plan (the &#147;Plan&#148;). The Plan provides for the granting of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock, stock units, performance shares and performance units to our employees, officers, directors and consultants, including incentive stock options, non-qualified stock options, restricted stock, and other benefits. The Plan provides for the issuance of up to 4,428,360 shares of our common stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 6, 2011, the Company approved the issuance of 885,672 options to each of the four members of the board of directors at an exercise price is $0.62 per share, The options vest over a three-year period and expire on December 22, 2015. The Company valued the options utilizing a Black-Scholes option pricing model with the following assumptions:&#160;&#160;share price: $0.64; exercise price: $0.62; expected volatility: 26.36%; risk-free rate: 1.11%; expected term: 3.5 years.&#160;&#160; On May 11, 2011, the terms of the options were amended to allow for immediate vesting.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, the Company approved the issuance of 2,000,000 options to a consultant at an exercise price is $0.46 per share, The options vested immediately and expire in November 2015. The Company valued the options utilizing a Black-Scholes option pricing model with the following assumptions:&#160;&#160;share price: $0.57; exercise price: $0.46; expected volatility: 27.77%; risk-free rate: 0.72%; expected term: 3 years.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The expected life is the number of years that the Company estimates, based upon history, that options will be outstanding prior to exercise or forfeiture. Expected life is determined using the &#147;simplified method&#148; permitted by Staff Accounting Bulletin&#160;No. 107. The stock volatility factor is based on the Nasdaq Biotechnology Index. The Company did not use the volatility rate for Company Common Stock as the Company Common Stock had not been trading for the sufficient length of time to accurately compute its volatility when these options were issued.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Stock compensation expense related to the options totaled $421,637 and $378,314 for the nine and three months ended March 31, 2011.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Warrants:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In January and March 2011, the Company issued 1,676,667 warrants to various consultants at exercise prices ranging from $0.10 to $1.50 per share. The warrants vest immediately and expire at various times in 2012 and 2016. The Company valued the warrants utilizing a Black-Scholes option pricing model with the following assumptions:&#160;&#160;share price: $0.36; exercise price: $0.50; expected volatility: 13.35% - 27.56%; risk-free rate: 0.16% - 2.30%; expected term: .5 years - 3 years.&#160;&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Stock compensation expense related to the warrants totaled $117,202 and $0 for the nine and three months ended June 30, 2011.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In March 2011, the Company issued 623,400 warrants to various investors consultants at an exercise price of $0.50 for registration penalties relating to the October 2010 Securities Purchase Agreement (see below). The warrants vest immediately and expire in March 2012. These warrants were deemed to have minimal value utilizing a Black-Scholes option pricing model with the following assumptions:&#160;&#160;share price: $0.39 - $0.64; exercise price: $0.10 - $1.50; expected volatility: 13.43%; risk-free rate: 0.13%; expected term: .5 years.&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The expected life is the number of years that the Company estimates, based upon history, that warrants will be outstanding prior to exercise or forfeiture. Expected life is determined using the &#147;simplified method&#148; permitted by Staff Accounting Bulletin&#160;No. 107. The stock volatility factor is based on the Nasdaq Biotechnology Index. The Company did not use the volatility rate for Company Common Stock as the Company Common Stock had not been trading for the sufficient length of time to accurately compute its volatility when these options were issued.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Registration Penalties:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On August 16, 2010, we sold 4,035,524 shares of our common stock as part of a Securities Purchase Agreement with certain accredited investors (the &#147;Purchasers&#148;) pursuant to the closing of our Private Placement Offering (the &#147;Offering&#148;).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to a Registration Rights Agreement that accompanies the Securities Purchase Agreement, we agreed to file an initial registration statement covering the resale of the common stock no later than 45 days from the closing of the Offering and to have such registration statement declared effective no later than 180 days from filing of the registration statement.&#160;&#160;If we do not timely file the registration statement, cause it to be declared effective by the required date, or maintain the filing, then each Purchaser in the offering will be entitled to liquidated damages equal to 1% of the aggregate purchase price paid by such Purchaser for the securities, and an additional 1% for each month that we do not file the registration statement, cause it to be declared effective, of fail to maintain the filing (subject to a maximum penalty of 10% of the aggregate purchase price).&#160;&#160;The Offering closed on August 16, 2010.&#160;&#160;The Company has not filed an initial registration statement and began accruing liquidating damages from October 1, 2010.&#160;&#160;Registration penalties totaled $225,183 and $75,061 for the nine and three months ended June 30, 2011, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On October 28, 2010, the Company began offering under a Private Placement Memorandum up to 6,000,000 shares of its common stock at an offering price of $0.75 per share. Purchasers in this Offering were granted registration rights under the Securities Act with respect to the shares of common stock under the terms of a registration rights agreement (the &#147;Registration Rights Agreement&#148;) executed in connection with the closing of the Offering. Pursuant to the Registration Rights Agreements, the Company will file a Registration Statement with the SEC registering for resale all of such shares within 30 days of the closing of the Offering. The Company further agrees to use its reasonable best efforts to have the Registration Statement declared effective within 120 days of its initial filing date.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 34.55pt; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the event the Company is unable to file a Registration Statement covering the Registrable Securities within 30 days following the closing of the Offering, or if the Company is unable to have the Registration Statement declared effective within 120 days of its initial filing date, then as liquidated damages the Company will grant each stockholder a warrant to purchase the aggregate number of shares purchased in the private offering at a strike price of $0.50 per share. The Offering closed on February 10, 2011. The Company had not filed a registration statement as required and issued 623,400 warrants to the investors in March 2011.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0"><b>NOTE 9 &#150; EMPLOYMENT AGREEMENTS</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On October 4, 2010, we entered into a written employment agreement with Chris Hadsall. Pursuant to the terms and conditions of the employment agreement:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Mr. Hadsall will serve as Chief Operating Officer of our company for a period of three years;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Mr. Hadsall will earn a base salary of $120,000 for the first 12 months, and will be entitled to increases thereafter as determined by our board of directors;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Mr. Hadsall will be eligible for an annual bonus as determined by our board of directors; and</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Mr. Hadsall will be entitled to participate in any employee benefit plans, as established by our board of directors.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Mr. Hadsall signed an agreement to keep certain information confidential and not compete with or solicit from our company for a period of time</p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On October 4, 2010, we entered into a written employment agreement with Joseph Connell. Pursuant to the terms and conditions of the employment agreement:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Mr. Connell will serve as President of our company for a period of three years;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Mr. Connell will earn a base salary of $250,000 for the first 12 months, and will be entitled to increases thereafter as determined by our board of directors. (He agreed to a reduction in his salary to $125,000 until such time as we achieve a positive net income);</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Mr. Connell will be eligible for an annual bonus as determined by our board of directors; and</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Mr. Connell will be entitled to participate in any employee benefit plans, as established by our board of directors.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 21, 2011, we provided written notice to our Mr. Joseph Connell, that his employment with our company pursuant to his Employment Agreement was terminated for &#147;Cause&#148;. Our obligations under the Employment Agreement are limited to the payment of accrued and unpaid salary through the date of his termination and any earned but not yet paid bonus from the prior fiscal year.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 10 &#150; LEGAL PROCEEDINGS</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 28, 2011, our board of directors, Mr. Randall McCoy (the Company&#146;s CEO), and our company (collectively the &#147;Plaintiffs&#148;) filed an amended complaint in the Eighth Judicial District Court of Nevada (Case No. A-11-634976-C) against Joseph Connell, our former President. The Plaintiffs in the amended complaint are requesting declaratory relief from certain allegations Mr. Connell has made in relation to partnership claims with Mr. McCoy, board membership, and stock ownership in our company. Mr. Connell has requested that the case be removed to federal court in Nevada and has requested that our complaint be dismissed for lack of jurisdiction. The case is pending.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 11, 2011, Mr. Connell filed a complaint in the Supreme Court of the State of New York (Index No. 103007/11) against Mr. McCoy, the Company, Joseph Rubinfeld, John Weber and Craig Eagle. The complaint alleges, among other things, that Mr. Connell is entitled to 50% of Mr. McCoy&#146;s stock in our company. The complaint requests an accounting from us and requests that we be enjoined from transferring title to Mr. McCoy&#146;s shares. We intend to move to dismiss the complaint because the Nevada case concerns the same matters and was filed first, and to dismiss based on lack of jurisdiction and failure to state a claim against the Company. The case is pending.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 11 - SUBSEQUENT EVENTS</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Management has evaluated subsequent events through the date of this filing.</p> 0.001 0.001 4500000 4500000 0 0 200000000 200000000 88236324 86406257 4428360 1330 0.001 0.001 5500000 5500000 1330000 0 899314 899314 43323 2261061 6000 2999705 757206 2000 -3160375 -3899019 -800529 -2000 3160375 6000 3899019 800529 2000 -6875 -262981 -2822 -6875 -262981 -2822 -0.05 0.00 -0.03 0.00 -1332444 -1332444 -1332444 85022991 73100000 83807964 73100000 51088 4564 46524 51088 1761384 6000 5178565 145000 145000 115000 1015000 -3007500 -1714860 -6000 -2119977 189211 508000 6875 0.001 0.001 1332444 1332444 -93018 -118988 433446 655208 -235000 -235000 6000 22500 4428 506000 212648 355275 -3007500 467550 3012575 1165000 1165000 251214 -75777 -444910 -9600 -9600 165000 -4499694 -6000 -5494444 -2135795 -2000 -3167250 -6000 -4162000 -803351 -2000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 5 &#150; LOANS PAYABLE</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In February 2011, certain investors have advanced a total of $85,000. These loans do not bear interest and are due on demand. In June 2011, the Company repaid $75,000 of the advances from the proceeds of the Preferred Stock Offering.</p> Q3 -5494444 -994750 Amendment to add XBRL exhibits EX-101.SCH 6 rgin-20110530.xsd XBRL SCHEMA FILE 0001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 0002 - Statement - Balance Sheets link:presentationLink link:calculationLink link:definitionLink 0003 - Statement - Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0004 - Statement - Statements of Operations link:presentationLink link:calculationLink link:definitionLink 0005 - Statement - Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 0006 - Disclosure - Notes to the Financial Statements link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 rgin-20110530_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 rgin-20110530_def.xml XBRL DEFINITION FILE EX-101.LAB 9 rgin-20110530_lab.xml XBRL LABEL FILE Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Amendment Description Current Fiscal Year End Date Is Entity a Well-known Seasoned Issuer? Is Entity a Voluntary Filer? Is Entity's Reporting Status Current? Entity Filer Category Entity Public Float Entity Common Stock, Shares Outstanding Document Fiscal Year Focus Document Fiscal Period Focus Statement of Financial Position [Abstract] CURRENT ASSETS ASSETS Cash Prepaid expenses and other current assets Total current assets Intangible assets Total assets LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES Accounts payable Accrued expenses Loans payable Note payable Due to related party Total current liabilities Total liabilities COMMITMENTS AND CONTINGENCIES STOCKHOLDERS' EQUITY Preferred Stock, $0.001 par value 4,500,000 shares authorized; none outstanding Series A 10% Convertible Preferred stock; $0.001 par value, 5,500,000 shares authorized; 1,330,000 and -0- issued and outstanding Common stock, $0.001 par value;200,000,000 shares authorized; 88,236,324 and 86,406,257 issued, 83,807,964 and 86,406,257 outstanding Additional paid-in capital Deficit accumulated during development stage Less: treasury stock; 4,428,360 shares at par Total stockholders' equity Total liabilities and stockholders' equity Preferred Stock, Par Value Preferred Stock, Shares Authorized Preferred Stock, Issued Series A Stock, Par Value Series A Stock, Shares Authorized Series A Stock, Issued Common Stock, Par Value Common Stock, Shares Authorized Common Stock, Issued Treasury Stock, Issued Income Statement [Abstract] Revenues Operating expenses General and administrative Stock based compensation - general and administrative Total operating expenses Loss from operations Other Income (Expenses) Interest expense, including amortization of beneficial conversion feature Total Other Income (Expenses) Net loss Preferred stock dividends Net loss attributable to common stockholders Basic and diluted loss per share: Weighted average number of shares outstanding: Basic and diluted Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES Net loss Adjustments to reconcile net loss to net cash used in operating activities: Amortization of beneficial conversion feature Stock based compensation Preferred stock dividends Changes in operating assets and liabilities Prepaid expenses and other current assets Accounts payable Accrued expenses Net cash used in operating activities CASH FLOWS FROM INVESTING ACTIVITIES Acquisition of intangible assets Net cash used in investing activities CASH FLOWS FROM FINANCING ACTIVITIES Proceeds from the sale of common stock Proceeds from the sale of Series A convertible preferred stock Payments of expenses relating to the sale of common stock Payments of expenses relating to the sale of Series A convertible preferred stock Proceeds from the issuance of notes payable Repayments of notes payable Proceeds from advances from related party Proceeds from loans payable Proceeds from advances from officer Net cash provided by financing activities INCREASE IN CASH CASH - BEGINNING OF PERIOD CASH - END OF PERIOD Supplemental disclosures of cash flow information: Cash paid for interest Non-cash activities: Issuance of common stock for the conversion of amounts owed to related party Conversion of notes payable into Series A convertible preferred stock Treasury stock Notes to Financial Statements The Company Basis of Presentation Loss Per Share Intangibles Assets Loans Payable Note Payable Related Party Transactions Stockholders' Equity Employment Agreements Legal Proceedings Subsequent Events Treasury Stock, Value Dividends, Preferred Stock, Cash Increase (Decrease) in Prepaid Expense and Other Assets Increase (Decrease) in Accounts Payable and Accrued Liabilities Increase (Decrease) in Accrued Liabilities EX-101.PRE 10 rgin-20110530_pre.xml XBRL PRESENTATION FILE XML 11 R3.htm IDEA: XBRL DOCUMENT  v2.3.0.11
Balance Sheets (Parenthetical) (USD $)
Jun. 30, 2011
Sep. 30, 2010
Statement of Financial Position [Abstract]    
Preferred Stock, Par Value $ 0.001 $ 0.001
Preferred Stock, Shares Authorized 4,500,000 4,500,000
Preferred Stock, Issued 0 0
Series A Stock, Par Value $ 0.001 $ 0.001
Series A Stock, Shares Authorized 5,500,000 5,500,000
Series A Stock, Issued 1,330,000 0
Common Stock, Par Value $ 0.001 $ 0.001
Common Stock, Shares Authorized 200,000,000 200,000,000
Common Stock, Issued 88,236,324 86,406,257
Treasury Stock, Issued 4,428,360  
XML 12 R4.htm IDEA: XBRL DOCUMENT  v2.3.0.11
Statements of Operations (USD $)
 3 Months Ended 9 Months Ended 46 Months Ended
Jun. 30, 2011
Jun. 30, 2010
Jun. 30, 2011
Jun. 30, 2010
Jun. 30, 2011
Income Statement [Abstract]          
Revenues          
Operating expenses          
General and administrative 757,206 2,000 2,261,061 6,000 2,999,705
Stock based compensation - general and administrative 43,323   899,314   899,314
Total operating expenses 800,529 2,000 3,160,375 6,000 3,899,019
Loss from operations (800,529) (2,000) (3,160,375)   (3,899,019)
Other Income (Expenses)          
Interest expense, including amortization of beneficial conversion feature (2,822)   (6,875)   (262,981)
Total Other Income (Expenses) (2,822)   (6,875)   (262,981)
Net loss (803,351) (2,000) (3,167,250) (6,000) (4,162,000)
Preferred stock dividends (1,332,444)   (1,332,444)   (1,332,444)
Net loss attributable to common stockholders $ (2,135,795) $ (2,000) $ (4,499,694) $ (6,000) $ (5,494,444)
Basic and diluted loss per share: $ (0.03) $ 0.00 $ (0.05) $ 0.00  
Weighted average number of shares outstanding: Basic and diluted 83,807,964 73,100,000 85,022,991 73,100,000  
XML 13 R1.htm IDEA: XBRL DOCUMENT  v2.3.0.11
Document and Entity Information
 3 Months Ended
Jun. 30, 2011
Aug. 01, 2011
Document And Entity Information    
Entity Registrant Name Regenicin, Inc.  
Entity Central Index Key 0001412659  
Document Type 10-Q  
Document Period End Date Jun. 30, 2011
Amendment Flag true  
Amendment Description Amendment to add XBRL exhibits  
Current Fiscal Year End Date --09-30  
Is Entity a Well-known Seasoned Issuer? No  
Is Entity a Voluntary Filer? No  
Is Entity's Reporting Status Current? Yes  
Entity Filer Category Smaller Reporting Company  
Entity Common Stock, Shares Outstanding   83,807,965
Document Fiscal Year Focus 2011  
Document Fiscal Period Focus Q3  
XML 14 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.1.0.1 * */ var moreDialog = null; var Show = { Default:'raw', more:function( obj ){ var bClosed = false; if( moreDialog != null ) { try { bClosed = moreDialog.closed; } catch(e) { //Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control // that somtimes causes it to throw when checking the closed property on a child window that has been //closed. So if the exception occurs we assume the window is closed and move on from there. bClosed = true; } if( !bClosed ){ moreDialog.close(); } } obj = obj.parentNode.getElementsByTagName( 'pre' )[0]; var hasHtmlTag = false; var objHtml = ''; var raw = ''; //Check for raw HTML var nodes = obj.getElementsByTagName( '*' ); if( nodes.length ){ objHtml = obj.innerHTML; }else{ if( obj.innerText ){ raw = obj.innerText; }else{ raw = obj.textContent; } var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g ); if( matches && matches.length ){ objHtml = raw; //If there is an html node it will be 1st or 2nd, // but we can check a little further. var n = Math.min( 5, matches.length ); for( var i = 0; i < n; i++ ){ var el = matches[ i ].toString().toLowerCase(); if( el.indexOf( '= 0 ){ hasHtmlTag = true; break; } } } } if( objHtml.length ){ var html = ''; if( hasHtmlTag ){ html = objHtml; }else{ html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ objHtml + "\n"+''+ "\n"+''; } moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write( html ); moreDialog.document.close(); if( !hasHtmlTag ){ moreDialog.document.body.style.margin = '0.5em'; } } else { //default view logic var lines = raw.split( "\n" ); var longest = 0; if( lines.length > 0 ){ for( var p = 0; p < lines.length; p++ ){ longest = Math.max( longest, lines[p].length ); } } //Decide on the default view this.Default = longest < 120 ? 'raw' : 'formatted'; //Build formatted view var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ; var formatted = ''; if( text.length > 0 ){ if( text.length == 1 ){ text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ; formatted = "

"+ text.join( "

\n" ) +"

"; }else{ for( var p = 0; p < text.length; p++ ){ formatted += "

" + text[p] + "

\n"; } } }else{ formatted = '

' + raw + '

'; } html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+'
'+ "\n"+' formatted: '+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +''+ "\n"+'
'+ "\n"+' '+ "\n"+'
'+ "\n"+' '+ "\n"+'
'+ "\n"+''+ "\n"+''; moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write(html); moreDialog.document.close(); this.toggle( moreDialog ); } moreDialog.document.title = 'Report Preview Details'; }, toggle:function( win, domLink ){ var domId = this.Default; var doc = win.document; var domEl = doc.getElementById( domId ); domEl.style.display = 'block'; this.Default = domId == 'raw' ? 'formatted' : 'raw'; if( domLink ){ domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed'; } var domElOpposite = doc.getElementById( this.Default ); domElOpposite.style.display = 'none'; }, LastAR : null, showAR : function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }, toggleNext : function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }, hideAR : function(){ Show.LastAR.style.display = 'none'; } } XML 15 R6.htm IDEA: XBRL DOCUMENT  v2.3.0.11
Notes to the Financial Statements
 3 Months Ended
Jun. 30, 2011
Notes to Financial Statements  
The Company

NOTE 1 - THE COMPANY

 

Windstar, Inc. (the “Company”) was incorporated in the state of Nevada on September 6, 2007 and is in the development stage. On July 19, 2010, the Company amended its Articles of Incorporation to change the name of the Company to Regenicin, Inc.

 

The Company’s original business was the development of a purification device.  Such business was assigned to the Company’s former management in July 2010.

 

The Company  has adopted a new business plan and intends to help develop and commercialize a potentially lifesaving technology by the introduction of tissue-engineered skin substitutes to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds and a variety of plastic surgery procedures. To this end, we have entered into an agreement with Lonza Walkersville, Inc. (“Lonza”) for the exclusive license to use certain proprietary know-how and information necessary to develop and seek approval by the U.S. Food and Drug Administration (“FDA”) for the commercial sale of a product known as PermaDerm™.

 

PermaDerm™ is a tissue-engineered skin substitute prepared from autologous (patient’s own) skin cells. It is a combination of cultured epithelium with a collagen-fibroblast implant that produces a skin substitute that contains both epidermal and dermal components. This model has been shown in preclinical studies to generate a functional skin barrier and in clinical studies to promote closure and healing of burns. Critically, the Company believes that self-to-self skin grafts for permanent skin tissue will not be rejected by the immune system of the patient, unlike with porcine or cadaver grafts in which rejection is an important possibility.
Basis of Presentation

NOTE 2 - BASIS OF PRESENTATION

 

The accompanying unaudited financial statements of Regenicin, Inc. (the “Company”) have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and with Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the nine months ended June 30, 2011 are not necessarily indicative of the results that may be expected for the year ending September 30, 2011. These unaudited financial statements should be read in conjunction with the audited financial statements and footnotes thereto included in the Company's Annual Report on Form 10-K for the year ended September 30, 2010, as filed with the Securities and Exchange Commission.

 

Going Concern:

 

The Company’s financial statements have been prepared assuming that the Company will continue as a going concern which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company has incurred cumulative losses of approximately $5.5 million for the period September 6, 2007 (inception date) through June 30, 2011, expects to incur further losses in the development of its business and has been dependent on funding operations through the issuance of convertible debt and private sale of equity securities. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. Management’s plans include continuing to finance operations through the private or public placement of debt and/or equity securities and the reduction of expenditures. However, no assurance can be given at this time as to whether the Company will be able to achieve these objectives. The financial statements do not include any adjustment relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

 

Development Stage Activities and Operations:

 

The Company is in the development stage and has had no revenues.  A development stage company is defined as one in which all efforts are devoted substantially to establishing a new business and even if planned principal operations have commenced, revenues are insignificant.
Loss Per Share

NOTE 3 - LOSS PER SHARE

 

Basic loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted loss per share give effect to dilutive convertible securities, options, warrants and other potential common stock outstanding during the period, only in periods in which such effect is dilutive. The following securities have been excluded from the calculation of net loss per share, as their effect would be anti-dilutive:

 

Shares of Common Stock
Issuable upon Conversion/Exercise
as of June 30,
2011 2010
Options 5,542,688 -0-
Warrants 2,300,067 -0-
Convertible Preferred Stock 13,300,000 -0-

 
Intangibles Assets

NOTE 4 - INTANGIBLES ASSETS

 

In July 2010, the Company entered into an agreement with Lonza for the exclusive license to use certain proprietary know-how and information necessary to develop and seek approval by the U.S. Food and Drug Administration (“FDA”) for the commercial sale of a product known as PermaDerm™.

 

The Company paid Lonza $3,000,000 for the exclusive know-how license and assistance to seek approval from the FDA for the commercial sale of PermaDerm™ in the U.S., and later for approval in foreign jurisdictions for commercial sale of PermaDerm™ throughout the world. In conjunction with Lonza, we intend to create and implement a strategy to conduct human clinical trials and to assemble and present the relevant information and data in order to obtain the necessary approvals for PermaDerm™ and possible related products.

 

In August 2010, the Company paid $7,500 and obtained the rights to the trademarks PermaDerm® and TempaDerm® from KJR-10 Corp.

 

Intangible assets, which include purchased licenses, patents and patent rights, are stated at cost and will be amortized using the straight-line method over their useful lives based upon the pattern in which the expected benefits will be realized, or on a straight-line basis, whichever is greater.

 

We review our intangible assets subject to amortization whenever events or changes in circumstances indicate that the carrying amount of such an asset may not be recoverable. Recoverability of these assets is measured by comparison of their carrying amount to the future undiscounted cash flows the assets are expected to generate. If such assets are considered impaired, the impairment to be recognized is equal to the amount by which the carrying value of the assets exceeds their fair value determined by either a quoted market price, if any, or a value determined by utilizing a discounted cash flow technique. In assessing recoverability, we must make assumptions regarding estimated future cash flows and discount factors. If these estimates or related assumptions change in the future, we may be required to record impairment charges. We did not record any impairment charges in the nine months ended June 30, 2011.
Loans Payable

NOTE 5 – LOANS PAYABLE

 

In February 2011, certain investors have advanced a total of $85,000. These loans do not bear interest and are due on demand. In June 2011, the Company repaid $75,000 of the advances from the proceeds of the Preferred Stock Offering.
Note Payable

NOTE 6 – NOTE PAYABLE

 

On August 2, 2010, the Company issued a $150,000 demand promissory note (the “Demand Note”) to NPNC Management, LLC (“NPNC”), a company whose principals also represent the Company as securities counsel.  The Demand Note bore interest at 5% per annum.  

 

In March 2011, the Company executed a Promissory Note and Security Agreement (the “Note”) with NPNC and three of the Company’s directors, Craig Eagle, Joseph Rubinfeld, and John Weber for $265,000. Mr. Eagle, Mr. Rubinfeld, and Mr. Weber contributed $80,000 and NPNC agreed to contribute the remaining $185,000 of the loan of which $150,.000 was previously borrowed and represented by the existing Demand Note and the balance of $35,000 in new funding.

 

The Note accrued interest at 5% per annum. The Note, together with all accrued interest, was due and payable by June 14, 2011. In June 2011, the Note was repaid with interest from the proceeds of the Preferred Stock Offering.
Related Party Transactions

NOTE 7 – RELATED PARTY TRANSACTIONS

 

The Broadsmoore Group, LLC (“TBG”):

 

TBG is a stockholder of the Company.  On August 30, 2010, the Company had entered into a finance representation agreement with TBG.  TBG was to provide advice to the Company and evaluate relevant transactions the Company may consider.

 

In addition, TBG advanced monies to the Company.  The advances were due on demand and were non-interest bearing.  In addition, the Company was utilizing the office space and employees of TBG at no cost.

 

For the nine and three months ended June 30, 2011 and 2010, the Company did not incur any fees to TBG.

 

In fiscal 2011, the Company borrowed additional funds from TBG.  Effective December 30, 2010, the Company and TBG signed a settlement agreement by which TBG accepted 666,667 shares of common stock in exchange for all monies owed TBG to date (approximately $506,000).  These shares were previously issued as part of the October 28, 2010 offering.  In addition, the Company orally agreed to pay a $200,000 success fee to TBG if the Company raises the remaining $3.5 million being offered in its current offering that commenced on October 28, 2010 (see Note 8 – Stockholders’ Equity).
Stockholders' Equity

NOTE 8 – STOCKHOLDERS’ EQUITY

 

Authorized Shares:

 

On October 27, 2010, the Company increased the number of authorized shares of common stock from 90,000,000 shares to 200,000,000 by amending our Articles of Incorporation.

 

Series A Convertible Preferred Stock:

 

In June 2011, the Company issued 1,330,000 shares of newly designated Series A Convertible Preferred Stock (“Series A Preferred”) and 665,000 Warrants in a private placement, The gross purchase price of the units sold was $1,330,000 of which $105,000 was from loans from certain investors that were converted and $60,000 of cash advances from TBG for the payment of certain operating expenses. In July 2011, the Company issued an additional 15,000 Series A convertible preferred stock and 7,500 Warrants.

 

The Company has accounted for the value of the Warrants in accordance with ASC Topic 470, whereby the Company separately measured the fair value of the Series A Preferred and the Warrant and allocated the total proceeds in accordance with their relative fair value at the time of issuance. The Company valued the warrant at $50,078 utilizing a Black-Scholes option pricing model with the following assumptions:  share price: $0.21; exercise price: $0.15; expected volatility: 26.22%; risk-free rate: .66%; expected term: 3.5 years. The value of the Warrants was recorded as a deemed dividend.

 

The expected life is the number of years that the Company estimates, based upon history, that the Warrants will be outstanding prior to exercise or forfeiture. Expected life is determined using the “simplified method” permitted by Staff Accounting Bulletin No. 107. The stock volatility factor is based on the Nasdaq Biotechnology Index. The Company did not use the volatility rate for Company Common Stock as the Company Common Stock had not been trading for the sufficient length of time to accurately compute its volatility when these options were issued.

 

In addition, in accordance with the provisions of ASC Topic 470, the Company allocated a portion of the proceeds received to the beneficial conversion feature, based on the difference between the effective conversion price of the proceeds allocated to the Series A Preferred and the fair value of the underlying common stock on the date the convertible preferred stock was issued. The discount resulting from the beneficial conversion feature was recorded as a deemed dividend in the amount of $1,279,922.

 

The Series A Preferred pay a dividend of 8% per annum on the stated value and the holders do not vote separately as a class (but do vote on an “as-converted” to common stock basis) and have a liquidation preference equal to the stated value of the shares. Each share of Preferred Stock has an initial stated value of $1 and is convertible into shares of the Company’s common stock at the rate of 10 for 1. The dividends are cumulative commencing on the issue date whether or not declared.  For both the nine and three months ended June 30, 2011, dividends totaled $2,444.

 

For both the nine and three months ended June 30, 2011, dividends and deemed dividends totaled $1,332,444. At June 30, 2011, dividends payable total $2,444 and are included in accrued expenses.

 

Common Stock Issuances:

 

Private Placement

 

On October 28, 2010, the Company began offering under a Private Placement Memorandum up to 6,000,000 shares of its common stock at an offering price of $0.75 per share.  Offering expenses are estimated to be equal to 10% of the offering price.  For the period October 28, 2010 through February 10, 2011, the Company sold 623,400 shares of common stock and received gross proceeds of $467,550.  Expenses related to the offering totaled $75,777 and were offset against additional paid-in capital.

 

TBG

 

Effective December 30, 2010, TBG accepted 666,667 shares of common stock in exchange for all monies owed TBG to date (approximately $506,000).

 

Services Rendered

 

On November 22, 2010, the Company issued 150,000 shares for consulting services rendered.  The shares were valued at $112,500.

 

In February and March 2011, the Company issued 390,000 shares for consulting services rendered.  The shares were valued at $247,975.

 

Stock compensation expense related to the shares totaled $360,475 and $247,975 for the nine and three months ended June 30, 2011, respectively.

 

Treasury Stock:

 

On July 19, 2010, Mr. McCoy agreed to deliver to the Company 4,428,360 shares of common stock beneficially owned by him with instructions that such shares be cancelled and returned to treasury.  Such shares were to be returned to offset the potential dilution caused by an equity incentive plan for directors involving the same number of shares that was adopted (see below). Mr. McCoy delivered the shares on January 5, 2011.

 

2010 Incentive Plan:

 

On December 15, 2010, the board of directors approved the Regenicin, Inc. 2010 Incentive Plan (the “Plan”). The Plan provides for the granting of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock, stock units, performance shares and performance units to our employees, officers, directors and consultants, including incentive stock options, non-qualified stock options, restricted stock, and other benefits. The Plan provides for the issuance of up to 4,428,360 shares of our common stock.

 

On January 6, 2011, the Company approved the issuance of 885,672 options to each of the four members of the board of directors at an exercise price is $0.62 per share, The options vest over a three-year period and expire on December 22, 2015. The Company valued the options utilizing a Black-Scholes option pricing model with the following assumptions:  share price: $0.64; exercise price: $0.62; expected volatility: 26.36%; risk-free rate: 1.11%; expected term: 3.5 years.   On May 11, 2011, the terms of the options were amended to allow for immediate vesting.

 

In addition, the Company approved the issuance of 2,000,000 options to a consultant at an exercise price is $0.46 per share, The options vested immediately and expire in November 2015. The Company valued the options utilizing a Black-Scholes option pricing model with the following assumptions:  share price: $0.57; exercise price: $0.46; expected volatility: 27.77%; risk-free rate: 0.72%; expected term: 3 years.

 

The expected life is the number of years that the Company estimates, based upon history, that options will be outstanding prior to exercise or forfeiture. Expected life is determined using the “simplified method” permitted by Staff Accounting Bulletin No. 107. The stock volatility factor is based on the Nasdaq Biotechnology Index. The Company did not use the volatility rate for Company Common Stock as the Company Common Stock had not been trading for the sufficient length of time to accurately compute its volatility when these options were issued.

 

Stock compensation expense related to the options totaled $421,637 and $378,314 for the nine and three months ended March 31, 2011.

 

Warrants:

 

In January and March 2011, the Company issued 1,676,667 warrants to various consultants at exercise prices ranging from $0.10 to $1.50 per share. The warrants vest immediately and expire at various times in 2012 and 2016. The Company valued the warrants utilizing a Black-Scholes option pricing model with the following assumptions:  share price: $0.36; exercise price: $0.50; expected volatility: 13.35% - 27.56%; risk-free rate: 0.16% - 2.30%; expected term: .5 years - 3 years.  

 

Stock compensation expense related to the warrants totaled $117,202 and $0 for the nine and three months ended June 30, 2011.

 

In March 2011, the Company issued 623,400 warrants to various investors consultants at an exercise price of $0.50 for registration penalties relating to the October 2010 Securities Purchase Agreement (see below). The warrants vest immediately and expire in March 2012. These warrants were deemed to have minimal value utilizing a Black-Scholes option pricing model with the following assumptions:  share price: $0.39 - $0.64; exercise price: $0.10 - $1.50; expected volatility: 13.43%; risk-free rate: 0.13%; expected term: .5 years. 

 

The expected life is the number of years that the Company estimates, based upon history, that warrants will be outstanding prior to exercise or forfeiture. Expected life is determined using the “simplified method” permitted by Staff Accounting Bulletin No. 107. The stock volatility factor is based on the Nasdaq Biotechnology Index. The Company did not use the volatility rate for Company Common Stock as the Company Common Stock had not been trading for the sufficient length of time to accurately compute its volatility when these options were issued.

 

Registration Penalties:

 

On August 16, 2010, we sold 4,035,524 shares of our common stock as part of a Securities Purchase Agreement with certain accredited investors (the “Purchasers”) pursuant to the closing of our Private Placement Offering (the “Offering”).

 

Pursuant to a Registration Rights Agreement that accompanies the Securities Purchase Agreement, we agreed to file an initial registration statement covering the resale of the common stock no later than 45 days from the closing of the Offering and to have such registration statement declared effective no later than 180 days from filing of the registration statement.  If we do not timely file the registration statement, cause it to be declared effective by the required date, or maintain the filing, then each Purchaser in the offering will be entitled to liquidated damages equal to 1% of the aggregate purchase price paid by such Purchaser for the securities, and an additional 1% for each month that we do not file the registration statement, cause it to be declared effective, of fail to maintain the filing (subject to a maximum penalty of 10% of the aggregate purchase price).  The Offering closed on August 16, 2010.  The Company has not filed an initial registration statement and began accruing liquidating damages from October 1, 2010.  Registration penalties totaled $225,183 and $75,061 for the nine and three months ended June 30, 2011, respectively.

 

On October 28, 2010, the Company began offering under a Private Placement Memorandum up to 6,000,000 shares of its common stock at an offering price of $0.75 per share. Purchasers in this Offering were granted registration rights under the Securities Act with respect to the shares of common stock under the terms of a registration rights agreement (the “Registration Rights Agreement”) executed in connection with the closing of the Offering. Pursuant to the Registration Rights Agreements, the Company will file a Registration Statement with the SEC registering for resale all of such shares within 30 days of the closing of the Offering. The Company further agrees to use its reasonable best efforts to have the Registration Statement declared effective within 120 days of its initial filing date.

 

In the event the Company is unable to file a Registration Statement covering the Registrable Securities within 30 days following the closing of the Offering, or if the Company is unable to have the Registration Statement declared effective within 120 days of its initial filing date, then as liquidated damages the Company will grant each stockholder a warrant to purchase the aggregate number of shares purchased in the private offering at a strike price of $0.50 per share. The Offering closed on February 10, 2011. The Company had not filed a registration statement as required and issued 623,400 warrants to the investors in March 2011.
Employment Agreements

NOTE 9 – EMPLOYMENT AGREEMENTS

 

On October 4, 2010, we entered into a written employment agreement with Chris Hadsall. Pursuant to the terms and conditions of the employment agreement:

 

Mr. Hadsall will serve as Chief Operating Officer of our company for a period of three years;

Mr. Hadsall will earn a base salary of $120,000 for the first 12 months, and will be entitled to increases thereafter as determined by our board of directors;

Mr. Hadsall will be eligible for an annual bonus as determined by our board of directors; and

Mr. Hadsall will be entitled to participate in any employee benefit plans, as established by our board of directors.

Mr. Hadsall signed an agreement to keep certain information confidential and not compete with or solicit from our company for a period of time

 

On October 4, 2010, we entered into a written employment agreement with Joseph Connell. Pursuant to the terms and conditions of the employment agreement:

 

Mr. Connell will serve as President of our company for a period of three years;

Mr. Connell will earn a base salary of $250,000 for the first 12 months, and will be entitled to increases thereafter as determined by our board of directors. (He agreed to a reduction in his salary to $125,000 until such time as we achieve a positive net income);

Mr. Connell will be eligible for an annual bonus as determined by our board of directors; and

Mr. Connell will be entitled to participate in any employee benefit plans, as established by our board of directors.

 

On March 21, 2011, we provided written notice to our Mr. Joseph Connell, that his employment with our company pursuant to his Employment Agreement was terminated for “Cause”. Our obligations under the Employment Agreement are limited to the payment of accrued and unpaid salary through the date of his termination and any earned but not yet paid bonus from the prior fiscal year.
Legal Proceedings

NOTE 10 – LEGAL PROCEEDINGS

 

On February 28, 2011, our board of directors, Mr. Randall McCoy (the Company’s CEO), and our company (collectively the “Plaintiffs”) filed an amended complaint in the Eighth Judicial District Court of Nevada (Case No. A-11-634976-C) against Joseph Connell, our former President. The Plaintiffs in the amended complaint are requesting declaratory relief from certain allegations Mr. Connell has made in relation to partnership claims with Mr. McCoy, board membership, and stock ownership in our company. Mr. Connell has requested that the case be removed to federal court in Nevada and has requested that our complaint be dismissed for lack of jurisdiction. The case is pending.

 

On March 11, 2011, Mr. Connell filed a complaint in the Supreme Court of the State of New York (Index No. 103007/11) against Mr. McCoy, the Company, Joseph Rubinfeld, John Weber and Craig Eagle. The complaint alleges, among other things, that Mr. Connell is entitled to 50% of Mr. McCoy’s stock in our company. The complaint requests an accounting from us and requests that we be enjoined from transferring title to Mr. McCoy’s shares. We intend to move to dismiss the complaint because the Nevada case concerns the same matters and was filed first, and to dismiss based on lack of jurisdiction and failure to state a claim against the Company. The case is pending.
Subsequent Events

NOTE 11 - SUBSEQUENT EVENTS

 

Management has evaluated subsequent events through the date of this filing.
ZIP 16 0001255294-11-000487-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001255294-11-000487-xbrl.zip M4$L#!!0````(`$M?$#_GMNBFP3,``)U#`0`1`!P`DTI.=7@+``$$)0X```0Y`0``[#UK<^,VDM^OZOX#5CO9 M2ZKTH"1+ENV9V=+8GL3)Q/993F;SZ0HB(0D9"F!`TK+RZZ^[`5#4P[;\F,S8 MNZE=QR:![D:_&V@PK_]Y/8W9E3"IU.I-I5D/*DRH4$=2C=]4?AG4^H/#DY,* M^^?;__XO!O^\_ENMQMY+$4?[[$B'M1,UT@?LE$_%/OM>*&%XILT!^Y7'.3[1 M[V4L##O4TR06F8`7%M,^:]>#B+-:;0NXOPH5:?/+Q4D!=Y)ER7ZC,9O-ZDI? M\9DVG])ZJ+<#-]"Y"44!RXRE^C_3JE^/@.XCGL&C5M!L-H)>H]FY;+7VV]W] M=GM+T!G/\K0`'5P'[A\[_?7UT,1R'W\R8+M*]Z]3^:926LVL7==FW&@%0;/Q MKY\_#,*)F/*:5&G&52@J?E8LU:=-\YI[>WL->NN'KHU$Y!Y'NX&OASQ=0$8" M;QF_1@F\C;)B0GEPIV%?+@V5&X=V[5#IAT9B95PJPOI87S7@10.%4PN:M7;3 M#S=B="/)W0:\]0-EJG=:S=W;UF='^`EY6AMSGA031CP=TF#W8@,Q\,;H6*0; MY]";#9.45BJ?;J8KRDPCFR>B`8-J,$H8&1;S[IZT/`%HP,>;J:,W&ZB[^/[D MM)B`?[@QG5H[J'BK0$W:3TE?+\2(D1+N3T@T:&$UG!)TVD'].HTJ[C4B?%-) M)3J'"FMX4-9*0JTR<9TQ&;VI]-.SD<79`](\SF*H4)G,YL73XKF,\,U(@@K\)<@^8>.']LPJ5L2S+-D$B[@\S#IO=%3P!'4X']!,]//EF'`%)-AN'J[ M6(Z'M'BW-@U"J9^TPF?_YBGY'.R5^!P\>S[[Y=R/S\%?P.?=&M`6=%^(/OOE M?'7ZC#AV7I#?<,OY^O@`SYE1H2MZ MUDSR"_BL:>?SM-)E3?I\::?3)!O7.L^627X!3\>D7$G+H5\&1VMLF0J>YD:\ M=57Y/HSQP/RK910([0;X@PDW(KT1A7/,-.C!.("^\QOP1/(*Y+'.6YQ[BC4Z M[IN57M^?!ZLT;H):0GHDE)Y*=1?:N_FRBG<38/]^B0N;&!H)N7],RGDAQC+- M#&@7;JTQISP7N)]P6RX&TX22H515=J+"^NO&31#7,1Z"51@>GZA(7/\DYENC M+%O>C=#*Z(YT"+)1V>4\V7YAX)_^U\(O3]\$]IR,[]BF"UO#+R=V-T(KH^O# MVPA'O(_Y><F=UNTI[HL_QN@K:/]5<>Y@H1P3EOEZ0/1K4#9H-V6#Q+]+<@\:6Y_>O_!1 MQ#T-DW8A9^HNZ'@RW=+`'ZR+=PU)&&J(!NDYGW-8]2/%VNUT6D') MT#=#?S@-6YDSI+[=U@-H@'0C^B#Y4,8RD\*+'AS`J5;A(]6]LQ/L[B[1M`6V MIZ-Q&[XUV^"D.X^E\8/FRK/ZP9X0C\$7A)1!WA?=#0N_3N6^DO&;"N:8I>-$ M#_949^(!JW@LV*W$U%GF3AGF*KZC7%SJ"Q%#YA.=<_/46MU:(F1+9$](XU9N ML-G;[>T]FLIU*WBX:K;*=K8-^&/)MN-%K[77:W0?B_APKOB>Z1ZYQ%5LI M/:8VG(>NL-=KM4O>?17L0]!NM=(N1)7MT?:C"+B@%8_/(;\]48<\D1F/'[KH MW0Y$^[UR%K,9_B/(V,[`F]W>3O/>9%P:VIJ:/U[Z.SNM4LJS#O=AF!\8N0CH M1,<15/;'?^10`S[8NS<[W=9>B;'KH!^&?+LD+NCM[/7N@[QDY^#*GXX/:]GZ M78B>@K`'9?C;$H9]6?OO\E0JD:9'(@V-3-!BMM[V^$><'20LS>:Q>%,9P:1] MU@R2C%W**?CM4S%C%WK*5=4^J+*!,')TP*8"SH#A@R,D: MC^48_OP]3S,YFA/>CU)%>*IK=YW9M]E$,$?+SNZ!V[WR#WH'WQ$Y,YXRJ4)M M$FTP=8$_&$X$0)E@>@047?&(,Q#B0"29F`Z%8=TJPW,8QA6,3_V42%R)6">X M6873QZ+.SA3[,8_GK+F',YI!E08Z4AC'W5<1$1T2"M(^9$UA#%P`M"<%3:@_ MF6;A!.IG0?,5;L;#F#(L&+&R[?[BY'NY6*Z78O<`F&4DS(0X-W2&QU"FP!LB MIRP48!EG20[X9&CY"F]E*.JE%16_#?)PL@R2IRG0!"H"O,XVTS+29@KZ`>L# M\1-.Z30`I?_O()(E'DZ0:Y%.T*XX4X#(,Y3H2F*NK`V!=P3;1<9.1)QX2Z)W M(21?PH02L/\I4'Y0EJD,_@2FQG(D4GZ%&[R9""=*QWH\9\,YB0>`&AWE(0D: MK47BYG]-*%B4$,;97?H)))3F0UA3ED/!AS08D6;:6%O[(^$:<)6:(1O'1EB- MF\ELPCYH]2=G'WG\"8+4E8QCX;WBPB/2F%5_B.O!A8CK,`99`:88+$3!"@$/ M+C04)N.P6J`PP25PH/:3TK/:1,^<,-$*K'TI$8*P<0C,+DLU%>(3XPD`N4++ MM1+[I3ZH$Q'OM8YHV)')QZP?3:6B4T."65K!^Z-^B7[F:5^H#$MY+)S=6V4@ M6H%=*3L70.41_'`@.NV#EV>@&Q:)$8NO6P.ILS6)PAJ`:2+A^'($20OC>886 MIO.4?9N`,$#;EASQ3'UGC2(4<0R*>Y)97""/(1Y&.T,,\SC+$:B`^@'L7>93 MJ[0X,H[!T%?YEU'G1T: M\#TA^KIJ$=%\Q!\"Y\"B4KOH5,2C6J9K^&]+Q-CP448AB26X:D5Y";ZQL@>> MQS%3.@-(X/)^%R&Z:>\\I]-<018T3R'E\;F&DWF5R,A5+#\)*SC(4R#M`$,S M+(1DZ0J6[K`#MME$0B2U"%`#4"7@YQ2/%5&FB8:X2NGUO&1_KQLW)=.K5<`[ MGDK([<_!5P)QI&68I(,I4)Q7F=NG!LZ>:W!F((!+L)9W,63Q7S(Q;T%B_JX_ M.!FPL_?L_.)X<'QZV;\\.3M]P2DZY@L\#*T&HZKGBH-)H.*-P$,HZ[,Q]<90 MEOKHN)+9WIW:VQA)IERX,%!%1&TBO#ME]18#CK-C3"?@M;"Y2J$Q,!VJ`YE` M5EZ$1\Q6C)R6*"Z'/#1D`GZ10^CIU8(VLRO(8SM@4/M7G?6)$D#@+'O.(DVV M"-CB/`(N@6TZLRM!)QH0PTCK3.$&-1@6E*#&6NZV2R&G$+K[@!LY#\[;)C0Z M`=]E_?8BJ[4>`$GD$8J7IK!OP9C`%#/GPI0F5PL.-`=O",\XGGM`C?T=HX$1 M19U%AH`T@2OETJ#,"ELNB=+Q)H*Z*D'7"T")$!@-(24MXK]"7S0%O9U0T@18 M?D1GU@ZH"&LR4`?BM<(D\>1=<7<1@VM?G=QQ2H4XKO36I:5`P_8!40;SSF? MICJ+^1^H.94"F;@N#ZQRWX/8P-QK/RVMT?%Q;7GP$V+F2,;":CW1@),&*':; M."-)Q]>N?L6]5`@_L*B7EVP5_OU[;?MEP-$8M?_"_?FF,GB3AJ,=$SG+;AFJ MZGQ*%1S:67E+@_(3#-!20;:"I20;:]?,@XQUF06%<,P/G<*C`4&M6*2;W)[V M4]4!#],1#PM7"J_CTL&(LP[GN85-8%!+FC,O6P=3>MV%_Z5L`+^P.8@0POH,9 M1N?CR;(_JSJW1'DE$00)J4'3]Z1LV*`"ZG#+::D>IQS4I\"12-#F%3D%2'#) MO6GK=\%]%Z10A`(94E3%[%XKR/\R[/0`&,.,&`^AYPI395^.";L_FQ9.PGE) M(@,@V(,&"&Y<@@0HP>=4]$.8S!'F4.=+RE+6/BM/*CEOT9XZ^[F(9^796&BD MWF%Z>A`(Z:AVNBUN8H5?*6;=^1#23008"L]SSY$&O%]C`K'*:O!BW\)&%^R9 M`J;8#8$?]`PD::J@J&0^A@B"5!?#QQA4$+*0S.X99N'@@?#81I!-K)@:3 MZ-P<-Q+""=84.`8U?T@Y.]08MBQ'Y=]HVJNY"^YM%HD!K":F6.WWS2`CT$"^ M%Q-M\L2XN59LRP&C<)")K'\0P+(IM9I8H[5K<(]NF%\V:QO!Y7A"IV(8,%S5BH[5EA#O\F\>ZVC7_D"%&" MWG0"Z9S"346PRQQ-:<-&:7\#C'"!)Q)@=F0+X(S%HJC&#%R,()2@&1@B1&-V M6'*8,?I!ZT/@$3BD=$*Y^-)N+$D0Z6.2MB(5(G/E`EAZR=51,D[[:V`&4;58 M%:&7*EU4W4NU_%/4ZJMU_S$WD.B/TW-AJ`67)LS_^M)^"^NA>K\-]?Z'L\&` MG1]?L,$/_8OC%VPH*.B0T@_CWF.X`)-0.:5'E&5@2X:%"T91ZO2..=!SK&<(KI1"+:IEV\"._=TO[XCP._2X$%NB> MW05+J)B#D=+5M!;QS%>FZ%%JGH;]FQ0JLTUXN`6<\)`^8114Z.^$1Y'_VRG= M3$;9!+4N^.:`#3'BFQIM`B>IV&?^M\H""R(PQ9_H$.A1M!&@4^E6DC6:SN])"L,N9%%BU_-$D$-6O+2HU6K:FUO530V>%PVL)T,"/2; M2DAG2:LBZ908V+R;^JUEY]&0>8%&^@4.=9;I:>46T6X2SP$D>DK4)L(^0RDO M\\TM;E6**QB`6&`4\&*W<@.V[GVQ$6CDWWW]*\T>.,XFL"IY212&8POK&!MM% M,*!J@Q](''[;"G:JK7:O"O_^[C8U]@%\YYO-*NJAGGYYKP5/K]QKXFY2J MV;9V'`3/=FG/&_Q-@O'V^L5,=(L]PL]W5+@X@+GCT.2NKT(#X2$8/21SM`>D MWMH\RRQK-O&!D%)K?2QL"PZ=Z9.-I"_/#D#`_7P,#S;X1K*+5[O5#EB#[\RP M7!6NWPJ#>^K[DT#.D0"4G]9=R.Z.9>RE`,@KS\E`?OKQHM8,`+-)7B*/?3;@ MFBJK[IC:-WXEN0DG/'57ZYQG@5$)SX0_*[>_.Y97J6^$.LDB1E=WTLQUT+O& MM"E^?.Y/>(NM*F-W-==PG%V+J<];9!,()MA19H^N,8B-\MB1@!=D\#^N$MGS M'7>-)*4W7I'U]D]%$J,L#72DV#;2;'9!2P-&_Q7"!AB3XOC!+;EX4'] MF%R(^3?I$ON(3+J2`$'G=#UB64NP'0D;"7TCDI.I#?:S"?`;N8:-1%E*5XBH M4YRZJT)IPGQJ0U+J>_3%HE4XY,;0/1+;#(@Q@5HF,`&BOD'LVR^N.+FVPUC8 M=L:+Y3Y$V_:?%E3CK3#[D57J5J%V+(A)[C(I:=HJ>N=`1CDV:C+LF4VIG0G[ M@WDZ8:-8SVR/LL5AV6%*VE>Z5P9!RZ_&=3`;4;XY`;&)X\6/JKNPA7]1J`(8 M;KEC1::#=T?Q'JNGSU$+BR*E+?IOBN5F^RPQST`@?]HNM4T< MM'=]Y1^YH+B.]*7D')8;2^FN[!0CPI1_$K;//'%MQ6+,Z?8-$Z#%4_(^5FBV MX7/:I"08JRI^.NFM#[)E3.[6@XO?%H%O7>Q@^%T;>R+C%N M^L\Z@G$)>87&]K45C5U_G/=_ZT/]^(+KQK-%=K3I0Q1T'Q1OI;\" MIM#N%9*#21!EKAIO[."W8_%2T>KENR,["C6@7*J!/I^>GQZ6FNRK[,.'PW)Q MA^]+4ZKVIK#M2Y_H5"PZ4)VCC%,TDG(F77Q)(RWWP*&UIB+>V&F+]5*)9.Q; MLKD_7OK'%*3S#?7#6/>F)+J8\".T6Q.'K5ZG90I^OL9U/WL_'7E:GX MR,Y"YV3DD!;^JF>K:%(8HAF7&?GK`7:8J^JF4%%@4'G5['4**W(KB\%-XBIM MQDEV5D>X^&&1!+,GG:?Q'-71Z)FPFR.%KB_N98MK=\&RK,/^VLB0Q_X6SJLV M4<#)YK65+L=M@EVV]HWFRYS`\%A=9C>_.EN*!(-U=7(%1)%%'N MRG7W+4E@.T7-YHZ_S4E;V^ET05NR;T"<],(-R=WKPV#_B'>E'_)6[T%/U"1WQG-HW2J,5A];W2>K`73_V_ORIO;1H[]5T%M M>:OL*I*+@P!(;Y(JZK!7]6Q):WF3MW]"(B@CRT,A2,E^G_Y-'W,`!$B``&5) M3E*5[-H@IC'3TW?_^O/1>T/&ON@>G*/W!"N2:ARVG/XHU-L7)`K9#M+]RZ:^ M@UZ=;"1=]?LI8?JU3?&M"+&'"R`]L+^P8',0:?AD%4=AWY9VZPY9^F MPO&"+BGP;:'!%34H1IMB1`28=Y74OHXCDL,%;\U0ENFF%`>MG5=$3YA,Q%E; M4(2OF\*@67GQ+:;R;ORR%32(0>SKY1WC.Q.30=M[A7XIDD((#>+!S=LIW5_J M<88_F<3$"'C]GN76[>[V$.PVP=D7!?:Y-!>9RR4^*]IZ*9D>99+I%)M[(/]W M(@R('*9#7BH!ES+XG9"[\6HELR)*"LI@$CQ*U$@$DB`(.D$0JEZM2;8]*L%. M)0J38#)(V&9\P]$0AJ4AMP@R\76^H=X.P,I]4W;YN:&<5\9;;MC:TNL5!GBT M7$D5O?`,'('KF.!6)JRSL*M?0GM+TB4N%K=MDE\RW_S4UVG,YNS`M+], MP%/MFEF$??JFT%:M86;NQKH%BIZ8?9K=G\\7Q__SV\6'D]-/5^;^_/['V>>7 M#+BJMF2T7GU9+#'63(U+S]_^E&$S=4?"PL#9')+%*:<1=7MJI#;$%$!YT8?R M>6BK3#T_)D0!2PC\TVL&BL5[+O1>*4KL,]6`51@,?B+>-;*V%!.^$)[;C"_D MHK1.Q_,R_(*MO`]"V8QCT-$@=Y&<*IMFNI#J>?6,&;4#,R"@2)HEZ[414TU! MGBB@DPX&7VZ7"XGSRFEAR@))10L`W"ET\(S1<'ZEO\L(D]FT(#R`MP7":/R/ MLDXI$1\'>*V,\X%:GMNW*8Z&-+P*U+LQO:-<`FDDJ9H6H:@E6HM<8B'AQC!1 M!SEMC@-1*5;Q.47:-.`**(<^1NVSV61^I\Z%9`-L-U4LR,U^KM=[HTP)48%O M9%I/;GLFYYAA,`7:ITO91E?'UN?%77)C]4,;9*CZ`MKGMU(VPGD`J$&P57#OZ:`$X5 MCIS&#C"RE6^++%S"2L";^]9Z9?=1WO)R]M<"Z!<@Y1MLJY@L*MRJ((,@4 M@R-"9T,33N?CYWICME?[J>T"]&N(A&5-#]PZ%(6*3U4V1V:K.V9)S)<$I"?" M4#)3ZEWF$A@3PD(<^0+KTA03+##/,HD1GJIGG9KT(0V(8*.*!'0ACU8]*13: MP9CD,=?S:,V#X+7)BG,@5ZMH,K$T2HQUM)Y.8_%/^D3.%SVQW2%Q#PE3S8M4 M,VR5K!W'BBH1816:, MMV1,)T6!II))V*++-A7?6O#V"B:[Z$[>B&P\[0=9\K$V\7^06G*JQ4 M+(_B+1&;,/B9C&V9`I5'R-65;'8P,W!\12+W`6R8:3'AMB.HGO7Z>KV"Q_`1 MQ#=C",V4V)Y'3*E:AGBF6W) M[8%4/B`DH7D"M>`YQ^9+)$$M!;\D*X58:+SLE2,GN)CR!$%=8*9! MG!WQ[FL'VSN:0K)HH>K![?3[_1^D?+76UB$M&GE5;QU-%\@(*F,_P;FE/;5& MJSQ\JWY>EAV09T&G0,X'5BD1H!?95'-5P:!\TF\$=?;*8?F94`C$V`+7Z_0S^Y'="ZPW8WL60W=F MP9+UJA^$'=^WBU.)\O-E!30I;RY_DRDH*0I#OQ.&H*>V,3=5IG.9>F26:@==,[.)7&,W*$E[U!I];=9#<`! M5@BJ.HX+X?9GS2]G5W3:YLU;C777[86<8^C^()T%& M*T3@A#XDQY9-@YQJY.WB(D!6C%Y@=_K"\("3DQN7G6FSPZ7CDQ8OOB,A//WV M7-FYBL[D:<\O)?N[U5;.39&%7H6/-\<+L\!H'$.WZY)Y*G/?^YV^L!L%?Y59 M?SHJ)Y99/'`OWY=D)HO9T]5RK4I08=S<6L9>8%P(S)X`<&'5M[!:+V5#'Y#" M)U4^9]64'K)]D=Z!'?!D(:(UK#"V"8<:9BM'ZY3H%<8\S]2`N2ES-$-PQJB4 M;*J7!)+&B^F]ZBB&@;HZA2+K,#"=;(PPQ?*HZWBZ>'C3,XZ`-YX3=7*'Q9E% MRAWQN&V MF'7CH+_\2_8)[V#\94**3#;L0WFT<%I7\D?R82SGZ("[BI@6$,GEJX#]-/J/ MV95/"'`!*II4072'"Z:AV4O?59H"C#8)9"4['`B#C\Q]H57MZ_0G:&>C8P#Y M2PB`;?MLCCRBD$.1D(6O,P7MRY,!%UK.!9T"4]-D?4X&ZXT;#/Q.$+KR9#"K M#$%]CI),8/MF>,]4*'[SAG$8)UN3`$']5W8O<,WA!K(=0"X'=4,$'!&16=7% M47<<<<%NC*]WR1+3'NK"LY_BEU9JR+>7EF88-+1?GA'T"\LS`M>HLS!*,RAB M%/2\H*`\P^DYSK;ZC")Z8.3]QTC8*H[)#?!+=81R@U#;8VDCJGF2E/#=>,F2 MV2P>)^#:PS$=JG'QZ?D0I17E&24B;Q''V"Q7Q3N-NQ098G/;+>D'N5MBF3<$ MH2;X+*;?S&N1:/==1AX;7(MV*Y8H%ZKXWP\+KP64:1=7+(6],"RX$G8O=`NN MA+P0/P2''KX(24F(QO5'5J;VB$R/[UE_9.5JC^C^/FK]4>'?(1V/6W]D';KV MZ.G=G.KQ(;-&2P6(^J[3"3Q*G;SR0F%L.OU*`2**`WK.BW=$9>7B@;W/"I3D MMN([D'*F+?/=L6"D17!72$D9-=U,L.-]M(2&.=,%`V,BJTUA5.O\5E5Z04&P M#3]^Y?1\VTBEHB!3;T<#W#`NN&!'&1AB&;GZ"O=#6!SB"US9'QKL*I?>R]Q0 M*FM_*]P+"LT-:!8K-#<S@!/M/S[$T;1%KEX@%O MBWW^PUZ'ZK)7\DY6^#I.V'%M8KU7=OVX_`^BXK:`"7'6218BY+99W73=SY.3 M.)ON"]5J^'0:R_A68PB+@XVF"`:5GSZL"BD@[*:GU",5E[)1R<`R,F.^6X57 MSC-2N^#R;&O]2T(AH%HQ01660P("\HS[A*A`\?%;.[RA$!ZY&$+.CQ)[UB6A M7B[)^EZAX^1XY4*K]]T$U(OUH1[::^(0M%'ZY+]-'#]D$\>ST.^*E$^F'KB4 M>N"%YZ,8U<@)9#;J(::ROW[']OR.[_;-DH."S(0)@Q$9>M$JT(FH:F1O+%0A M"Q6(84*EN?/Y*WZ'AH\8_/J&-,MZ"8%,!9T+&`^T4A#P+212I$`23$3R_4EL9/ILO"/T?M-3:4QWMD$1\1#02V>B5Y=*3QC=CJA M;6TTQ?^,#R/UZ#W)-GZYL;MVU-JYFY!6AO8W_*:"#40Z7FN4 ML1_QC;IZ=NY&*1"1YF/@;[)64S^B&+0D^Z6QIY$:)FGH'"2Z94(X*%XS* ML(BWZTP#[D0A'R&X-C##TES2E35^&&9:R:K:NF.1!!D-.D=[._NU*W M6A%Q=7K,GZ^YA$(AJ(*A7EY.1)`5=N*GXHL\UG],>8G2S7I,D_42JV-P;U,Y M+0JX"LK[A#Q'O%QA`"(90O@NEA1`1IV]L0U76U2V)--Q-9T)HH&0M&.-#5KK M(*(!_^OU>[Z?GRCW%&('9Z2[<&!&+L`F;@GW#R(+43R];-\S5IM\!GYM7-(< MO^C8TA:V03LE"V3'E3\&>0=E"K:(A++4U@U%,%CA;5PXE%YDA)BPLI'"70$$ M/ZGKLR;`1MVHFH(C;3`)D)21YA'/E$K^VHAFYM(E!;:#V?3%N-3F594Q"#83 M2JP#(B/51B8U0Q<&::4DTRZ>&>(L'B91&G]V_O84BP&!/BTA'POI M3X)Q%@#^#4W`O]./EQ\N_OQX>O[9&KW_='H*__22L:@-:Z5O!!AR2,D/2XCP MD5T8JU/,(R4??UD*0?!;-!8J:KJI*DFQ<\DG.0I*316]].V/$2^&:G/>,Q)8 MT)D#0VW$?B;QQ+J0"&5(QP55T1H5J*3!<>P.ES?BGH(1CG'FP_'L!N5B.4"- M@Z@M#/(#*898#&YV7.$D68)WY"(EY"AT,J/!I",+G"-Q&%&RBW^:@*L?I;G9 M1+`7F_6CC_CI0+4X6X29P,.8(U2'4%[7B_DZS5*,=)13CM;KW\RP-UC,8^IW`SOW"^<_F50L:W()RQ,2F%/RL#&-%Z480+\1 M2ADQCNZ$AX3.RSQ&W/K%+'[SB!O]'!1..>7%NL4JT2L4CWPJNN4[FNKLEJD& MC(=8MB^-E:05FLH80@*;`R>0E;!<2`"A/D-\DEXSQ(J9PH-GM0-GI@PA;8Y\ M%DG05QV4.X8`O@Z^T73."['$0AS@;<1]`RJ&6+@`5+),DUEBU'$90+X2*@F$ MQWJ..0MYF1E&!7XP9OPN>=\EP3CO94[S%D%T`4>M5ZCMO\%L2TR!X'TRACU! M@07/;0#QFO&02QW=C>&*\6TT_8CS:M/1?"P.!FQ\``R+TR>!@^_8IE_\X?3] MZ(-U^>GB^/3TY.S\_:/XQ$^G!.'"",QP5%]/3BS?`6OPB=U;%]< M,8A1"XMK/2:HQI.$.B8%96NJ$3B/[Z-Q9+T^!AT.U3JCKF"TP.L/PZ![_$;! M^>1%"E`/5G2\U(:*ZK.4]!J4;)")-QU"5M05QH'"""J?H-8/G.$,/+C8VEC* M$%/+0"IM%HU1G5"-(%00D::9B^OV);FC7*U8=4:!4-WSW>$3Y>9$\2R=#3>: M/O`+<(Z[/J[>!@'\'5BTK$8:IS$UP,^@VTN*Z$DLQ!^"9L(!0.<5'0#A*6Z\ M2:Y*6W:-F)PPOI%E+Y03PBG^>[U,4G'&.#X`3P&7%U+\+C[.HA7?E:GTGSBK65P/_<,6Z!*CZ<['\RWJ-16@6%;9YMAW^XCCZFAB< M90B`HBF7,.&2YE0JM].8B\F'J"\+<#\FWX7]?,O]S1!&OTU9O9O?"9K>,+I\ MRG@KVDQYI!":Q%?3/9$\GB6`^3*U*`- M"A-D`-T3,P]`'Y!71!?9Z0P0^B^:[$J5(W";$":#+H*URI!Y'5,5`980TLW" MFR!4JQ`D/'@-82)FI(W)#X&Q!,@;Z*ITN$J%4@V\CJI.++IS^`.H3%@3\`7& MY@EZ-9DIYC`X8M96>4CFRR7SOHH16:T5)YA_:BQ6"_5AG)M?D_A9R^Z[1J4E5Y MBUJFJ@4&&@Q<+_#<_A:"*AY<"QPT"/IVX/IA;6(D7)KQ8#,QU'<'7F"<4L$" M>])0OAE?T^3M/)G^_:?5G:1R?O2U>KDM.7BF[;"OM245D4-*2B M!FXH6L\'KQ+?KU=ONO M#V&W[.!`U!?Z>"V^WC9>O^?FX+$?@9-];/9V[W?0&>D_&`X]Q]#ZQ2OM34\; MG%%]L0I\\I@?7X6Q,O3T/<_U#D=."XSX/IY#A'8T'X_&T,U-!9?W,:/CM\&1 MKALX=F!XICO6;$YB%2;-D!AD+/?#TU>7K]WA`Q*:S` M_=E-;'+(JE3Q#,LA/L"HB1;N1M=S`ML+C9,M6&@_6FHS6=<3XM-VA@>@I38W M=0>V[;L'(:4NVW2S?%.'$#5BI`5.*6<4N;24 M11M1T4RJ[:3A#&L8TQ7__4E\O6I%C@4#DS<+5MF/D#;,S8HKU1:7;N`.!\X! M/KJ^M'0'KGL(0EHP,"\@>=NF(,RQ6N;]=1=O@[UVKM&8L1I]8E-F:K9X"PQT M&BWGD/F722OA&24WPFP[@5$*N6!,598J"]=U[9YI9>]8NCFEN_EO6V#Q$0G= MS47;MM1[3$IWLMQ!MO1$3L/,AG=;$7B.Y[G]OA'6*%EL?YK:D(,U5JLM$0^_ M`_7%Y"/0U(+T_%<,19'Q>'0O#,/;^!S;?IF'Z1Y<:(2UT1C*R[C-NB;?EF7^ M?-MUAT-#F^U)T>$^;`?SEWQ8Z#FYA.^3^[`=/%UV8M[`#H=!_RE_V/:+\=@G M=ARE7_9-UOJ./1@8:7'QJJJO+\G#9@/0OGF0-=X.`KI.EK<"L?N(KS+J2(/X M^[SN$EO)SKCQZB2F_V]#4?<#W\WM=O%BCP#BPZLNW2GC#&-SWHKH^5X0# M/_#;(/R29SP#)1\6T;P==L!"0+/4+;?(/E2T<5DKK5/W-!I]K1QP?S'YL)C? M?HZ7L[;BB(Y33E;QJJW0V?8Q55^X]KG9C7>HY-Z=S7ED56,INVNG&A'0QE$U M(Z!^7DW\QJ\@L@O6KTBY"ONWJR&[3NCT!\%NR@O6;Y7RVBJR6TE''ISL^J%? MQQD.P[`-RDW!\(EF15Q&R]6WUD3U8"BH+19$^?4:TM:V>*ZR9&WSQAZ4RN5= MVR&S,9=1,CZ.[I)5--VHL]SSE(KSGG9,QXV"/U<13;=7V:&W2RK,? MK26!Q@V7>M_[7S'^611TJ$?:`:/392O6-LL:;$;>*SZ;B]\`/,,)_Y(3;*/Y M&/-MHS2-B]$%:^OWH6<[`U,\[$/)P;ZGG>1_6\343UH(#3EXA-WED23I9?0- M<$JAHHV`0SXDT36,X&C)&NQ[7K\?;/N>*I0<['L.PRW[$E.76P+?=^VMS++/ MYGZ*&4Y&Z""`,94_;D5XN%[6$RU;K`%1[?0A5%^NOKV^YQZ8UN$E_^+=8BG= M=HS`B'\W#,?#N>-MT=(PCKD7&0?[EMH5VJ[?^L=D&@]'-X1WS+FJXX4PSXO, MS:8E,-`A6=(>N86$%DFO41.S,\VQF(LETV0QOY@0)3,0H=1MY;0A!'T[R#7] M;ENQ,7T'TW$',!=BS>/XE9;.]-,:JJ%JV@:+R9&'WP[*>C0]V6+ MZ=;5&M'5Y.CV6[#VM;(=UX=[U7`G+B;M%_0Y3N#K!N1=*S8EK_6SJK)F[?C) M_ELB=*:PGOX/FR07DR.$507X/ZU.W=)^%`)8M!.' M#.QM1!8NW!JY!SG(RHO7/M+&>Z4OZ2(3HSC8\69D>ZW56Z6[I6%<(YX=A/T"K5P.<86'P3!;IU:'B/:_H85T_'?^@-JWSN\/^YD$SW?_ MACT:NQS/#X?^4_J&ALW8;7Y`6^W\H>N745AW_5;O6>W%ZQL;3K#E>&IO_AZ8 M`9[G.VTMWR9K9O08!G]9=^FY+5; M!U)JW'L$S]83D^2X0)SW&(WOH:ARS',I<60P3GX9X#05!#=.8VN*I;D\_ODZ MCI8(XPQE-#2&01SQ>!T#IO(X%A2/>Y:@`,<'T^KF=$?*"],@8MM6`YR)$,;. M7:JA#>0LRZ>4'621(:3FHF[,[*X68.%^0Y'0E`1_SOQ9]5G M&_[N_>V7K6_:3-?!&<1CV7\YNA$_7&.:Y`2]S&RU5HU6FTT=OGNM=JBKTJG3 M'0[[H6\W(:X9AF2],JVVT"%U*F0V2["[:@/WN\5OJ+E*S6\!/A_!Y`=8X"1. M;Y;)71TDL7^H'^,XI_'8^M^C3Q^L^.N7Y#I9I721BA80!/SMEZ_7RVGR%OY7 M_.O_`U!+`P04````"`!+7Q`_8LU9\-P$```+*```%0`<`')G:6XM,C`Q,3`U M,S!?8V%L+GAM;%54"0`#GI-*3IZ32DYU>`L``00E#@``!#D!``#56EUSXC84 M?>],_X/J?6D?C`UL,@V;=(>29(<9FF1"=J=O&6%?0!,A44E>X-]7,K;#AS]$ M-QF[>2!8OEZ7VM)KIR=@%;=%A_OOT;C8`X+[!)F!`G`2;W,+'E^[8N+"R\^FYH>6:XG@J9K=+T43C:S M/DM*['>02-*3,;P1#["*]U/E,JC0PARYJ9EKAMQVQ^VV6VL9.BGY,8."4WB$ M*3+_];;(5GW\,KSSS*"GA8D6P%2?A3=,$;4Q*HE%#%(#CV>9"YA>.49^UPCN MGW5]L]0'&U^U6>J\D,1L:P=Y)Z+[$U/#X'@.H&05G%SC-US_`0L=[!P4"3`] M"4RNYX\A,PD$AGQY/[U?FFJB2:^DJ-SK[1`-L)S?4KXZ"="1TX_AN>,*Y).N MJTP+03!]7:H*5+5G&3(M<1#1F-F1/M[S@+72)1K"=!X#]#\FI1XVOKIDMI&+ M4H_=K_JRA+;N:,__S>'F)UZ&KZ-!913J[XDY2NP3-"D>RH,]#-143"[V-4L@ MQ&5QBN4DKHV1=&<8+[WXH@14R70D5M?UVTF)_)`,/_>EU``&D3#9F2Y`\01H MO.RSB?#`QJL/K4F/`I#;4X?8=I3MBP!Q$8+0?8SOI[-@$>PI>GRE22P\&2VV MN\;TMQ;N!"8:)^2(8Y9NNJ*:L&=B)TJW7E'R MHFH<]?%]8SGU^R9VU'^LE_J\J!I'_74$3_P1-'<0/F!Q8OVR]K83[*Q>P4[D MHG%:[D19W=0TJ1O(+5S%DC6-]['BP8;VW[E/0U(8Q MKOB)0O&M^K%ES?NGF/6#^_.B&-]P'QW_%&K6?AZ#T-NW;\]SF4/-/:`=W=41 M-RY[!WRQX*Q2FF.SFOL_.T&*HFN<#/TP)"9B3!\P"8=L@)=$O3[T.;QQ*K*N MN3.T$Z4BUL9I\P@*$P;A#1:,L)G4=WK1(HK[I&N8DH`4]8!&`9B4UEAX2EYQ;L7&="/ M!T!?_1"?HEW/=X5X_#9&AO"L%*%Q1(GGFR.T>#4C@WEN7H8@,J!<5U70![$S M4AQIF5$V!=J=PP!.]J[Y,"]8Z9%_`5!+`P04````"`!+7Q`_/!\>K/0"``!' M#@``%0`<`')G:6XM,C`Q,3`U,S!?9&5F+GAM;%54"0`#GI-*3IZ32DYU>`L` M`00E#@``!#D!``"]EUU/VS`4AN\G[3]XVV2\N_GYTV)EU+/Z`E%VUBG_<]C[^3YM$XY^@1E&92M(*H%@8(1"HS M)NY;P6T''W=.VNT`:4-%1KD4T`J$#(Z^?_R`[-7\A#$Z8\"S!)W*%+=%3QZB M2YI#@LY!@*)&JD-T1_G0E<@SQD&A$YD/.!BP%9/$"8IK8481QFOXWH'(I+J] M;GO?OC&#A)#1:%03\I&.I'K0M52N9]>10Y6"]U+W3/Q5]=JX9[E/J;%%]3"* M2/B-1(V;>CV)]Y,X7M/:4#/4WCHVM9GQ@FIP@TPJJZ%LB74%6K-$%RVYD"DUQ=1;281>C'!/N`S#K@A'=1Q' MM;'.@G*;)#:C*"T@+ M7KCT%?1:@9LIV,V-L!&'+M7G=;3F:6"7D&9N!02(;$CW@W+7@YT^@-&KT&P51 MWUJH=-@%G#$+HHL%-DU4;;UW8<(0&TJF,62AP>ZY?3*]`7&3" M.>1=4!OBSDIWSTHYWXRP$.R>2TASO"E:J7G7.0D].N3FU9.RE,\RVV(FF-M8 M+^SC##>,C7V9@ZPD=X:O/)-ML=/:EZL(850JJK?V!19-Y&A&OVW:Q<>NQZM; M)K^!VOMI."KC=XJS^.#U;/%2-O1E1OYU^ZPKCF//N?\#&4D`G1%/EM@'7.*L]Y;Y;'DRG7.JA`OM0B)&1R(XQ\A:HZN%XFV3FR\66 M_`-02P,$%`````@`2U\0/]>6WLH#%@``)"$!`!4`'`!R9VEN+3(P,3$P-3,P M7VQA8BYX;6Q55`D``YZ32DZ>DTI.=7@+``$$)0X```0Y`0``W9UK<]LXEH:_ M;]7^!ZQGMWJFRHIE.\DD3F>Z%%O.J-J1O9:3WJFMK11,0C*W*4!-4HX]OWX! M\"+><*&D@"?;']()>0[T'O(A[I>??WE:ANB11''`Z/N#XQ?#`T2HQ_R`+MX? M?)X-1K/SR>0`Q0FF/@X9)>\/*#OXY6__^B^(__?SOPT&Z#(@H7^&+I@WF-`Y M>X>F>$G.T$="2803%KU#7W"X%E?891"2")VSY2HD">$WTA\^0ZNSTU/+I!.'3,/LO=?\Y M#.CO9^*/>QP3Q%\$C<^>XN#]02F@;Z%?-P M(GDR_@Q26HA_#7*S@;@T.#X9G!Z_>(K]@_SARR<8L9#+":/H2/@?4;+@+]L7/_16_-#Q:_%#?\HN7^%[$AX@8/%6XLN>SF5/R79/ M?./G_DGS`H1L]Z1+GE79H;AXQ?]6$4Z>$E[P$#^7+M+29'#RIV2^FZ5=I,Z\ M2KJAR"Q95'TBHA0:B')G^.IT*..]_3B9?N4%S'I):#*B_`--@N19E#;14F:V MH_LXB;"7Y`G)*-X?=/`[JBL5*8RB7"Z./$/,F<61QWB!L$H&8?IT4_=YQ):= MY&0/B75P^AK>%[^7/ETN21%8Q2PBL:P&='JYY>BZ/NU,Z3+DGJ*F1>C@\^S@ M;[DKXKXH=48E[Y^/-C^V#5990#*8F'@O%NSQR"?!D:SA\+](Y`;#XZR8_1._ M]#55<4L6@5!.$U&UJ46M-G.!E$FD($AETSLP!F%U/C(D-K:RIMD?%N>S<@J&0626C9@0(C79E"C8R8R2M$3?O@XX\'[OCR;:$5;WM MBH4V43D"Y7L@WGR+(&5A(6SZ?,M%DT&TES6QU.Q95"%]V8O1!QX@+\868RQ`O6N*JW7=%0ZNLG(+*31!OOTU1_:T7-D@8]?JN M+TCL1<%*5%9UP53,G+_Y%I$-`$HVL#AH"E/C4++M@XKS=10)$M6+$H"NDA' M[]2-A:!T>K+2!ZM`*5$/T4H\(C&W)%64H]TB1I/N?EZ()%ZGZQ MFI5;=EHE5I&IF``BI4V7HC\LFW*0V?8'Q,WZ/@R\RY#A^A"-PL8M#"WRJBB4 M#`"!T%2EP"`U1-*RQS*&+9>,SA+F_3Y[P/QQ7*\3.;6&YUWJ;%'KY+B\L0B@ M5NIH/`"!9"%3U>$N/9%T/42I,RIY]]DSNVD(7O(K;949I:7KWEF%U'K_;,T, M!$%Z;GX94$R]@,?%XD`S-:6;JPO"M@E& M`-?%KW?^MA!;Q[%P16R."F>4>Z/_SOW_!P:56^:M MU1`,8#IUC9[HS[>WX^D=&LUFX[L9)&JL<.F3$S,@0,DP(`$)A7,67+:Z#><4E,8UOG=^"\5IO(K+"@3]^6A$:DQ'UKY,'$E7R+45X5IXN MH>@02ID9"S2*2NL:(M\P1$][(RX9`L4P&!I8V`/:(FA$JF/C8 M@"*77X!D8D(3+C2X#XD-'4IKEYP8))>)49B"84>OKS$T55B#0BB5KOTZ^LA( MU#D(F-=?D=.>9T!ZT5`:K!9 M>$*"SUYN"XS"N>@A@`'C%<,T_YA4V7;%Q&D)V"*N4N:5[H.!I$54H_(D3&!E M2E.6$`,'51.7'+2)*W-0O@^&@Q91=0Z$"2P,+M;DCMV24.YR@J..A9.UMTMX M.H94YLK2%0QRW?0V9H"L"4H8BE)_SF64['4RZSZ;<-8MC+Z;;'9--3`$*:7I MN['#C1LX8LR1]L:(`0Z(5&AQ`(>!F#@;)&(:D>CD.F=4K.`@U%-CH?5P.@1O MEEX9F5>;@\'(K+'1`73]Z=/D[M-X>I?V,IY?3^\FTX_CZ3F8KJ#.?=]0>KN[ M]6__`#W:G?NPX?99W_"T""]:TWYYN;FG>L9"T]+QK!"5U-HLD+H9&'#4VEIF M>:26^5J,?Q^^&`Z/15T9/0H_]/+PU7!X*#9@C=-E&GB=/+`H^"?QWR'**$%L M?^LV%'OXS4@D1G7,$!FMG>W79Y9<[-*G-NT=*#M]C6Q(.J`1.A[^!^*EXB/A M+3Z7`[/CP]36^*R4B#X0`%8HV\G\Y-^C[+AW:KJV7+ MHW097M/,=:VL362]*E:VZ1U+@[!&I2M=;1:WYW#O3E+@5-"]>7-XO#E\/7AR>O_IK!=XC>G!Z^&?[U\.WKA@4X)D>^+Y<;X/`&!_Z$GN-5 MP!LZJN$!E;73P1B]Y,KH2[LI&%[U^AKC*X4U$C,Q!P%%7NH`@Z5;DN"`$G^, M(\H!CT>>MUZN95_;!9D'7J!J,-@XNB3,/I`R;&8O,-Q92VWTH*9W$=XX('\= MB5TC?/)(0K:2*YIX'K<`TM]_%Q$[*;_D< M56.$)([/4)*9YS7`EX%+V)*)IAP-1L@%NWU/ON^K#K\@"30RFE MM??+QB7SGQ"1#C"0,J47?H==&B*UX\\;.Q[9Z:#2.48Q+Z+03TW MA@)-;^J:$UWAI;,#Q85E057G8>_EE`T7K26.VJP?'IJEB\H&(`?:DJ3.P'X* MDKT/%G9LJUEY]C2DV*659N'6.W#=M2K&(F$VSAH;>AI;9EJ/GJ"S:9-IS"%" M9EG(M6ZK"JTIU@A+VPY36O<*E[H%IC"%"Y6VQ*P"!:F\K`P[I9'8#%#EEKV- M]%6E*H?Z4C,PU*BU-;K)\_$]@,Q,J,>6I-B(TS"M66GM=C\@K>3J?D"MIF`8 MTNMK[@DD="U\I<9W/;[4R6JJCJ?)7T'A@@:H+J!.2W8;SN MZQ6)L%C>D6VE9]KC5&/O$@BC[#(A2F,PR)@4UADJ[(%M4O"14"XL'%%_Y"\# M*@^F3H)'DH6EB-[HY9(LRQ#*?!E#*Q*962S`\:>4U]XGG]69T+ZR15S)'`[0`3E@C=[;- MQ7LN$ZW*0C`TJ92U3UAB0$O`(HJTHG_%8B,M9>&E*;25F8P:/F8:VYDX^ M<8Q$_#DYC$(A1NP]G>KG);-M-=S@Y)0CJP`J2&D]X-!E([-1-9=;B6?-_#_G M3G^!P=J$)H0_I223=4'N-;M&-RT=[QBMDEK;+;IN!H8?M;:67:*E95Z8':*` M>N%:K*]#>"G.,_UG6EEB]/O5<5;DP!/FY-PR4 M*O"/'G$0BHT:[UAI4#A;R_(!QX%G\PG9I-);MF0?HC+C,BI(9PFAZA,3S1ELZ7Q MI=UDSE#C"X'Q191.R!5G%EZ&[)NICT[OTM,9QDKQBK.+&_9@*+40J3VK6#@A MZ05N#@ZOJPAU-Q$3U6S_P_/GF/@36O1VC[R$5\#E2F\]@MLDY+A6NV6@M8IM MQU3`0+RU],:,UM'L[^CRZOJW&;J\O?Z$KF_&MR.Q!2L:G=]-OAB/Y/G_U70Y M;EVSV)RM<0FX^*&= M&W6*-9BCTL@0FW\HQH7.BV&ARW14J/8PNSH[6Z_9.:!B%:>U9^\D;R6WP>:^ MQ@0A3W,#5X@;=-K.>(-1=BL&`$3>V6W((/4`,`Q3EFXQ%"/,H1%FEOJ#C`2U)5&[)-E[ M&;C?.!I-X0?^+Q+7:F,R*=FO".[PF^9CX%^UV!KY(ONVLQD<_$'(YZ,]O'W; MQ/K])+H$K/\2;%*"ENWO%$5+B2!OAM4H(/?X/QN2^N/R*8UB0!/D;8? M;]AYP`+J2-)N(TA@ZLZ=);<-)1B[+D%3.Z&/)-['>*@V(0`46P1J0;,F%>A4 MFZ6;QD,GTR_C68?Q4(=;^.+G;#QCY/VQ#B(BJ_C\"?AK$2S1MO9LG9UN[=LI MH,HVOU:>8&#M)+=9/^`N<9#WX`[ZH]07+@.*J;>'^H(V(0`46P1J0;,F%>A4FZ6;Z@N7D^EH>K[?^H)B M&)^+]PCQXTO^:FFA74-GIL<'`V7&\EO!BBUUKW#I2UQ&9W:^J3;B[` M*P`HYIZB2"\O+'&$SO5@<.Z5-6U`6NI:/>'RIY.[$XDN[UJQ==W?NWW18,:P:!S;V!5Z7<$2!1Y6_GELB#LV]PE#Q; MYF]-E[YR-I5X59Y6MP=#F(5(?3Z&_4>1A67_BM(DQ%G5<$Y\W41XQ3!5CH4T M[?JBJR)3A90T`LE169D>GE!8PLVB\KKF)8OR\EW&QO]=^E;4HQ=;IM47=IW# M5:%IG1!(?+NJ[Y(_LOD\\$@$`W7[WN^=N\^ACFOL-IX!!M_.DI6C46)CK]+I^>UX-!NC MR12)4;.>EA>J5GO)M5)NEPZNY..;);Q0T4TFK2AK'7\'YCJEO?+JG^J<[GE[8/5>'^PJM5ZM0[DF#PWP;FPF=LV@I MUXJ:MABR]7:ZVU"WD"HK@>UW?0V%@B7O)$?Q%[(XK7<$&N>EN5SGAP* M-ND!V1TNWZWZ!@?^.5X%7+[F*%6E=1^[B2LDM^TH7C,%PYQ>7R/GDW5"L1Z, M4R1F&4I?&!SE7\R4OS_^U\U4-.JW5'POB@_$D"GNGJSK"N4^'D*]C-XE33"L M[RF01F.)T8',8/>X1\N>/HEB]X[KN1Q$'2W%>K;TM-%CU5,R.+D]4M@F@.K) MPCH/."C:R&RTE4KC@^5)%3(S%@.(I=U:N`E>IHL7V3?>?I=[#NVQ,UXQ$6,3 M%ZN,4%E/QNB8@+,)&5L%5DS*Z.3=.Z1;2VX>C%WFL3(`*2H/[`>:D%$YVSE; MH)%O:7O.>/TIV[A9\;W;N_=VYK9%4,J#N#6^O=.\I6#ED=W?=S1JBR/EX?E>X;H[LWKD+78'2AW4< M4!+'%R3VHF#5<,4R"0(L2UL+">2 MQZ*_2/8N47\6+&@P#SQ,DVSG"]X@NF%AX/%"^HX\)1]"]9$ZNR7ILM3;1_#E MDG"7]'HG>8]!M)U.(7L?RXG"X+]^W(8,Z=F$N-&KS\-0%"'H#D.IN8!AT4YG MZYFLW`5)'QB<38IUV.GJ[4V?DHDU*T_'?=ZVH=3ZOTUN8+BSU]IRXF;FR1NS M>UEPKZC5R9E'64M\(Z^M=J*R=%:WTTLMJG?M9KTS8=;6S'_$Y,4;2),7I:2T MU1)AO]CP[Y9X)'@4,CMD2%NFY3*+VBG<E\_AH M+$9=&.U`#P$TX2CB6O)YPS MV<%#J$V'GZ6OTPI@EW`J%3X;Q][!VT9MHY4B?%&V)D5TLL``<;:^C\D?:_YE MC!_E)GBF4E%M[W9RJD%V=3JJPA@,6":%S2FGN3U*'7J:75X9VOV"P[5YQ%I: M.9[9;STZ716G'(F6MH=(6O?TY/=X>`Z<=V&CLOY2"I]#M#E$)WM!PK&G]]/[ MV1APWNJ.`32[?--DT)_S!/\BMK',S\O($I/'9`L``00E#@``!#D!``#M75MSVS86?M^9 M_0]<]V7W098O3;=QD^THOG0T=6./Y:2[3QF8A"1L*4`%2%_ZZQ>`2%T)XH`B M#:2S>4@<^1SHG.\##G%P.7SWX_,LC1XQ%X31]P?'AT<'$:8Q2PB=O#_X-.H- M1N?#X4$D,D03E#**WQ]0=O#CO_[ZETC^>?>W7B^Z(CA-SJ(+%O>&=,Q^B#ZB M&3Z+?L(4CJD[!$],?Z;.(P9K+D1RWF,EVWQ":%?^,GA\UC: M?8$R^=')T?%Q_^C[_O&;^Y.3L]/OSDY/@4UG*,O%LNFCYZ/BST+]74KH;V?J MKP,C[IGQP='??__H1J@B)\4&II5JI MTCM^^_9M7_^V%-V1?'[@:?D=I_W2G&7+\K>D1G[-$D'.A#;OFL4HT_W)^C61 M44+]KU>*]=1'O>.3WNGQX;-(#DKP-8*3#X[8.(TI%[V:QE_"Y$@+"?!`5[ ME9<^T;[%G##I0J(FUQ;8MV2!^)\&B7^EWSZ(&$AK$F7158HF!@*V9(#`?QL4 M\)5^>@7\`HN8D_GZ_,:$^X8H$/XW8<)?X;4/%LYSKER](D*F)__!B->'(+,X MD(WO@F+#YKV_B="O.$U_INR)CC`2C.)D*$2.N8$6BPZ0FW\&Q0T(!W\$?69I M+B'D+WKQ3M02LR,+).3[``DQ^.TQ95B,X3L\9SPC=+)87JS/'`PJ0%K>!DA+ M/0K^V-&]Y%R&U`GC]>G2)_+L2C0G[?+C1&XD$SD8O>!*'YHA_A-!/E)]L=JOCXR]*HF_%R ME^>6"0+8MX"I[CT\FOLV$$*"6\P%+&)!CVT:&A.@MQW-$DLOG.:8"RP?:33;% M?*.S&``':7K=S+#SX>!]&'1!B&E&03\9P'MZ6'A>DW0`TGEC`P+&?UT"C]EJ81)7/Z>R\3&,L.! MJWM=(F\Z$75%)SA.8:E#G8+7-71G_*NY"SN3B&.64W6P]`7)&&QYM!N$_:ZN M`Z!F=A\"(X7G.*EPC"8?&8UM)(&4_2[).Y/F`$@8)%XS1,M>9HI\&R)^U^#= M"*ER+@S8]9'K>M@W1?RNK[O!7N5<&+!?Y/B>W>%4SG226\0=8Q98V^_"NQM9 MCI"$P>.NB^!9&YR=;G)-QPAF=#0X(NP,P*'O)OML::8<%@-J7YED^K:.=.J< M4742!LOLS.+=71LBL&):.;A,7]T5'E9!@4#))$+\*B]!:19$C/T9QDJWO5VPLK)FDH M(=TD)6Z$6%P.@Y<[G"%"<7*).)53#3&(XWR6ZT3J`H])3$S/.&^P\NWB!!S%$\6K ME@UL%@V>/<-)[.9VT+[SY+!&DRT':+@K"BUAYK MC?Z^H?Z/_Q]S?84T5$)^P[7-B8[KMYCK6P6@S-2L_#4>A'4#)HR8N6GSXC[( M(,^FC),_5D.WEL1=):\G9]MASX1$N*SIJ[DNC)4*7@_AMLG6)@*ON4XTR.1H M=UXL6M?R>O*V*0E`++IE`ABSC-)>#]SNB7Q740J">&V\J93T>K*V%:3;C3"M MKXLZSL5`FEY/Z38ES0&3X$@$QK-:#:\E1UH@+>S9UXZAM:'0*/U5GK&V^!X& M01NKC0LS(>NJI:370]1-B:GQV>/BCJ7L[7)AY]NMA9V57L3&T9JFS^M%,9OA MI6&651RCM-=MHD=,<^-86/W:Y^*+!>;-W9Y-?\((/D5GI9/BFJ+MVG&-O-?, MW($(J\MA,+,H_I\.:#)(9H3JTKL9><2%U09^K%I>4W<[],S!E9#8TL^P#TC@ M1+V:0=JW48-[.]\T"'M-[IVXJ7XN2UZ30C1^0^V%0-:09ED!FA947^*&F M+,"NI->$$(@SL_@0$AW:)=LS9%/&[Y59=PXJ70P#_8\XLSX[MF3\WGUU1[_2 MQ3#0OR"/),$T$9N[9@8>C-)^+[^Z,V)Q.PQN-KK-X!&15%T<0"$,8 MG/V*R60JK1H\ROGI!'_,9P^8%Y;NE+`=)/_-A;Y]9^"R<6M^K^NZ<[PG;(%L M&^R^G&ZY:_"F=M=`*48+S2`.@BX=@1\`K5#Q^WA4!MURII[ER8>73P(G0[K, M&@=Q)I_R^JQQO8=-&@KD0*B1Q*T'9$.@PHBW@<^#.N%X#\Y:G1H!+\&<+@*E MC.P/3&#_EV!6CP^ABGC$C,8DQ1MP2!1:B1[=?%4HIV!!`:9+M#LZ.SB8J5>C M_*'Q9.,/F.K[>"@]9[1XT_<51EEN/*SFH.^WBFV7U+!&>(3T:/GZ=_5*PNP71?^N+-`.[@>PQKP><6Z+SMH> MX@+JGS'*;%6>5:>6=LJ:@CL5K#&ON^^OTJE<0/V3=JH]NE#3#M/-R8#7ZC!_ MVNX!7_/9>R'3]PF&#OJ*.WIA3%\,=@]EWBS:6,:N;WV^'9'?` M@B:ZN!ZW?\"N;B6`C8`JHZ6_:4E,<:)N))NC5"*V7AM*\P4>.MUH(QT MD_KO@3`#N_BJE-R,04<1[6I^*W9W0XP)G*ZX*9[#;%P>\`$-&)L6E)EN\M26 MF(%!\XK$5):_<:#(H.^WD'IW9-7"%<9,8WWTJ\(&JKC@S?B:TM=;.UM0"_`T;>K MXK?^>_OCS@1*>/3IMYX!."OD_-:%;Y^H#??#8Z=\1E\Q7@9P;;'\_^9;N``, M.K3EMYY\^RP[PQA&3X`#L?=BBN]2]>UP[@Y8&$1KH^74FR7;>T`&8NL4_%9" M;X=(.R#A$%=#$9R,D+/Z5H[*S36;HTS&6?^;RA;:OIPX'%`.G#CE2RO47=(0 MWN.1S^>I7FQ':;G8/J1CQF<(4K8?J@TE/^1,TA&J,.)I619#O(U337U5 MHS24OY#320L48?!5=BSUZE_YXVJ;DB85[EX0$:=,Y!Q;!NK^S4)[0,AY:EO@ M!M)5EI=>;L:+(O0S=AS0*2CK$!O ME163V-6W&V@P"7NM!]`,^7J_PQ@OVL:%>QPERYNG=SC&Y%$9[C""&K;EM1K` M'LPV12T,XM=/F$@GJ)"NJK>OP.EV:L'K3?YF)#=`*`QJ=U\!K0"`$^N@[_6& M?C-:G='IZ*EX.9NG3!\K&4PXWLRFMV>5E:)>+[(WG$K6^!S&V+G&$Y3^@K), M]@X9UL^9SE4PA61[0%VO]\D;/N]<4`F#R%'^(/#ON?3L\E'?>K0%/;.\WUO= M#:.DTI.=7@+``$$)0X```0Y M`0``Y5G=;]LV$'_>@/T/G)ZV!UG^:(+%M5LX25,8R)*B3HN]%;1TLHE*I$92 MC=._?D?JRW8DQ9.9F?3J4/>OOGE9X)_HU]=EUPPB((A.1>^.^6A>$VN:`Q#\AXX2*J% M?$T^TR@U*^*"12#)F8B3"#2@(-MI2`:=;D")Z^Z`^QEX(.2GC],2=ZEU,O2\ MV]O;#A??Z*V07U7'%[O!S40J?2BQY(+Q+[+?687(^YQJ7.IW>SVO^X?7.[KI M]X>#X^%@L".TICI5)71WUN_DY,2STD+UGN9J+J,">N`9\9PJ*)%1REKT&5>:IQILH*U0"V]!3XG87XYJ'`,]_"[?;<0:]03Y6[H#0I M34*JYA8Z%]28<,%Y&M<[&FCIZ;L$/%1R40LD\TN[AXTV#9""65:UY*RDAMW' M]].KTL"\Y#I'[L!48P0Q<'TA9'P.(4TCC/_?*8U8R"!PB*9R`=JDGTJH#XTX M1?92S@5F*=9@OF+6DH1A%N/"3R.3(D,I(KA!ML0\8.%MHII%#U,_-;PF/'C' M-=-WI@YD;)$=PH*QTZIA]L*=[6X!A(PS2PE+I4=<4IBN/U(>D`R'K`&-O&V( M->!407#-W]CG1()"&&MTB0NY8:[28.33R$^C_6PJ*K4F^4(1X;UB?DHC4XVS M)8!669`WEYJCVL=0FM,)\K#F=B0S?+E1_$`E^K,$S9!E34@WY7.DC\V/&U-^)%0J`5\L M"M&"X#%!2JRU+_#_B7G1AWZ$D-C^=6AZH[&CF)D3G'QM*2$<.Z8_=TTCTST: M=+^@:QWLF@H5`]W2O]JOMQV-?.,"@DK_'LJ]_AI!!)XMFF$#M]9$9]29-N8? MUK8A9A],#N\0+D=TOJ_+:`+1$_IZ:?`/ZB1FW[Y.;B7L$[EZ5NUR4(>Q=/9U M>+/:GLC?\W*3=7?S0<&K)H7\?7N:&*'C0FK"[PTD;=-E-A=?"M]"M9B8-[>P M<\V2V^OC*-59J:!BN@^)*@S[D2CL'D&B?29LH&$IU(ZZ'D1:E5ANA;4KG]:9 MNXW.MHUY>,3^K0/\X\-A5A[!9H?+@5TR9=WR*C,TJ7)B4J5W_"_)/([(0RSR MFP;;TICFYTO;!#^9*RVIKQW+NGW:KW1I_C1VM$RQYCB+\+?*G#O9N[V0&N(1 MQ41P8T_2()7YG4)VLF8:B,+X8HJ-D='"0*0(S'1J--]+D2:%(D.5-A=GN!6H M"?YXAR`E!#,M_*_V^JYPK%7C0?K96:4+T3P;"\>.CTA,;SH5"PZ:RKNG'4)-5+(=EW<^VUP;]&O"_O/*TLT*%Y M3Y5*&SB7HA_,=Q+C^<.^VTH3X2EP[`+,]'$F>/Z_@0N@&N>4PHM]#!Y9XPL]6W>U^%F/3?Y5Z/W M;%VD=W8"%N&[50)<@:K_@@^J/8-4K.%8>PRW.=5D\./=J^I?A/9"`^D;2JTN M[FOTX]ULOO'9[HMVT7QV7=%IJA@'I`Q0````(`$M?$#_GMNBFP3,``)U#`0`1`!@```````$```"D@0````!R M9VEN+3(P,3$P-3,P+GAM;%54!0`#GI-*3G5X"P`!!"4.```$.0$``%!+`0(> M`Q0````(`$M?$#]BS5GPW`0```LH```5`!@```````$```"D@0PT``!R9VEN M+3(P,3$P-3,P7V-A;"YX;6Q55`4``YZ32DYU>`L``00E#@``!#D!``!02P$" M'@,4````"`!+7Q`_/!\>K/0"``!'#@``%0`8```````!````I($W.0``&UL550%``.>DTI.=7@+``$$)0X```0Y`0``4$L! M`AX#%`````@`2U\0/]>6WLH#%@``)"$!`!4`&````````0```*2!>CP``')G M:6XM,C`Q,3`U,S!?;&%B+GAM;%54!0`#GI-*3G5X"P`!!"4.```$.0$``%!+ M`0(>`Q0````(`$M?$#]0:4R1+`X``,#)```5`!@```````$```"D@`L``00E#@``!#D!``!0 M2P$"'@,4````"`!+7Q`_N&=I=6X%```R(```$0`8```````!````I(%'80`` M`L``00E#@``!#D!``!02P4& 2``````8`!@`:`@```&<````` ` end XML 17 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 18 R5.htm IDEA: XBRL DOCUMENT  v2.3.0.11
Statements of Cash Flows (USD $)
 9 Months Ended 46 Months Ended
Jun. 30, 2011
Jun. 30, 2011
CASH FLOWS FROM OPERATING ACTIVITIES    
Net loss $ (4,499,694) $ (5,494,444)
Adjustments to reconcile net loss to net cash used in operating activities:    
Amortization of beneficial conversion feature   251,214
Stock based compensation 899,314 899,314
Preferred stock dividends 1,332,444 1,332,444
Changes in operating assets and liabilities    
Prepaid expenses and other current assets (93,018) (118,988)
Accounts payable 433,446 655,208
Accrued expenses 212,648 355,275
Net cash used in operating activities (1,714,860) (2,119,977)
CASH FLOWS FROM INVESTING ACTIVITIES    
Acquisition of intangible assets   (3,007,500)
Net cash used in investing activities   (3,007,500)
CASH FLOWS FROM FINANCING ACTIVITIES    
Proceeds from the sale of common stock 467,550 3,012,575
Proceeds from the sale of Series A convertible preferred stock 1,165,000 1,165,000
Payments of expenses relating to the sale of common stock (75,777) (444,910)
Payments of expenses relating to the sale of Series A convertible preferred stock (9,600) (9,600)
Proceeds from the issuance of notes payable 115,000 1,015,000
Repayments of notes payable (235,000) (235,000)
Proceeds from advances from related party 189,211 508,000
Proceeds from loans payable 145,000 145,000
Proceeds from advances from officer   22,500
Net cash provided by financing activities 1,761,384 5,178,565
INCREASE IN CASH 46,524 51,088
CASH - BEGINNING OF PERIOD 4,564  
CASH - END OF PERIOD 51,088 51,088
Cash paid for interest 6,875  
Non-cash activities:    
Issuance of common stock for the conversion of amounts owed to related party 506,000  
Conversion of notes payable into Series A convertible preferred stock $ 165,000  
Treasury stock $ 4,428  
XML 19 R2.htm IDEA: XBRL DOCUMENT  v2.3.0.11
Balance Sheets (USD $)
Jun. 30, 2011
Sep. 30, 2010
ASSETS    
Cash $ 51,088 $ 4,564
Prepaid expenses and other current assets 118,988 25,970
Total current assets 170,076 30,534
Intangible assets 3,007,500 3,007,500
Total assets 3,177,576 3,038,034
CURRENT LIABILITIES    
Accounts payable 655,208 221,762
Accrued expenses 354,077 138,985
Loans payable 10,000  
Note payable   150,000
Due to related party 2,000 318,789
Total current liabilities 1,021,285 829,536
Total liabilities 1,021,285 829,536
COMMITMENTS AND CONTINGENCIES    
STOCKHOLDERS' EQUITY    
Preferred Stock, $0.001 par value 4,500,000 shares authorized; none outstanding    
Series A 10% Convertible Preferred stock; $0.001 par value, 5,500,000 shares authorized; 1,330,000 and -0- issued and outstanding 1,330  
Common stock, $0.001 par value;200,000,000 shares authorized; 88,236,324 and 86,406,257 issued, 83,807,964 and 86,406,257 outstanding 88,237 86,407
Additional paid-in capital 7,565,596 3,116,841
Deficit accumulated during development stage (5,494,444) (994,750)
Less: treasury stock; 4,428,360 shares at par (4,428)  
Total stockholders' equity 2,156,291 2,208,498
Total liabilities and stockholders' equity $ 3,177,576 $ 3,038,034
XML 20 FilingSummary.xml IDEA: XBRL DOCUMENT 2.3.0.11 Html 11 91 1 false 0 0 false 3 true false R1.htm 0001 - Document - Document and Entity Information Sheet http://RGIN/role/DocumentAndEntityInformation Document and Entity Information false false R2.htm 0002 - Statement - Balance Sheets Sheet http://RGIN/role/BalanceSheets Balance Sheets false false R3.htm 0003 - Statement - Balance Sheets (Parenthetical) Sheet http://RGIN/role/BalanceSheetsParenthetical Balance Sheets (Parenthetical) false false R4.htm 0004 - Statement - Statements of Operations Sheet http://RGIN/role/StatementsOfOperations Statements of Operations false false R5.htm 0005 - Statement - Statements of Cash Flows Sheet http://RGIN/role/StatementsOfCashFlows Statements of Cash Flows false false R6.htm 0006 - Disclosure - Notes to the Financial Statements Notes http://RGIN/role/NotesToFinancialStatements Notes to the Financial Statements false false All Reports Book All Reports Process Flow-Through: 0002 - Statement - Balance Sheets Process Flow-Through: Removing column 'Jun. 30, 2010' Process Flow-Through: Removing column 'Sep. 30, 2009' Process Flow-Through: Removing column 'Sep. 05, 2007' Process Flow-Through: 0003 - Statement - Balance Sheets (Parenthetical) Process Flow-Through: 0004 - Statement - Statements of Operations Process Flow-Through: 0005 - Statement - Statements of Cash Flows rgin-20110530.xml rgin-20110530.xsd rgin-20110530_cal.xml rgin-20110530_def.xml rgin-20110530_lab.xml rgin-20110530_pre.xml true true EXCEL 21 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\X-S,X9&(T95]D,64P7S1F-F5?.#AB-E\W9#9F M8V4Q.3)E9#8B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I!8W1I=F53:&5E=#XP M/"]X.D%C=&EV95-H965T/@T*("`\>#I0#I%>&-E;%=O7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA M'0^4F5G96YI8VEN+"!);F,N/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$"!+97D\+W1D/@T*("`@("`@("`\=&0@8VQA M'0^2G5N(#,P M+`T*"0DR,#$Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^=')U93QS<&%N/CPO2!A(%=E;&PM:VYO=VX@4V5A'0^3F\\2!A(%9O;'5N=&%R>2!& M:6QE'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M2!&:6QE3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^4VUA;&QE3QS<&%N/CPO'0^,C`Q,3QS<&%N/CPO'0^43,\ M'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)FYB'0^)FYB M'0^)FYB'0^)FYB'0^)FYB3PO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQAF5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,#`L,#`P+#`P M,#QS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^)FYB'0^)FYB'0^)FYB'0^)FYB'0^)FYB'!E;G-E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^)FYB'!E;G-E'0^)FYB'0^)FYB'0^)FYB'1087)T M7S@W,SAD8C1E7V0Q93!?-&8V95\X.&(V7S=D-F9C93$Y,F5D-@T*0V]N=&5N M="U,;V-A=&EO;CH@9FEL93HO+R]#.B\X-S,X9&(T95]D,64P7S1F-F5?.#AB M-E\W9#9F8V4Q.3)E9#8O5V]R:W-H965T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)FYB M'!E;G-E M'!E M;G-E6%B;&4\+W1D/@T*("`@ M("`@("`\=&0@8VQA6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA'0^)FYB2!F:6YA;F-I;F<@86-T:79I=&EE3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^ M#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\X-S,X M9&(T95]D,64P7S1F-F5?.#AB-E\W9#9F8V4Q.3)E9#8-"D-O;G1E;G0M3&]C M871I;VXZ(&9I;&4Z+R\O0SHO.#'0O:'1M;#L@8VAA6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE28C,30V.W,@9F]R;65R(&UA;F%G96UE;G0@ M:6X@2G5L>2`R,#$P+CPO<#X-"@T*/'`@6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE2<^5&AE($-O;7!A;GDF(S$V,#LF(S$V,#MH87,@861O<'1E9"!A(&YE M=R!B=7-I;F5SF4@82!P;W1E;G1I86QL>2!L:69E2!H=6UA;B!S:VEN(&9O&-L=7-I=F4@;&EC96YS92!T;R!U2!K;F]W+6AO=R!A;F0@:6YF;W)M871I;VX@;F5C97-S87)Y('1O(&1E=F5L M;W`@86YD('-E96L@87!P6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE'0M86QI9VXZ(&IU2!T:&4@:6UM=6YE('-Y6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE2<^5&AE(&%C8V]M<&%N>6EN9R!U;F%U9&ET960@9FEN86YC:6%L M('-T871E;65N=',-"F]F(%)E9V5N:6-I;BP@26YC+B`H=&AE("8C,30W.T-O M;7!A;GDF(S$T.#LI(&AA=F4@8F5E;B!P2P@=&AE>2!D;R!N;W0@:6YC;'5D92!A;&P@;V8@=&AE(&EN9F]R;6%T:6]N M#0IA;F0@9F]O=&YO=&5S(')E<75I2!A8V-E<'1E M9"!A8V-O=6YT:6YG('!R:6YC:7!L97,@9F]R(&-O;7!L971E(&9I;F%N8VEA M;"!S=&%T96UE;G1S+B!);B!T:&4@;W!I;FEO;B!O9B!M86YA9V5M96YT+`T* M86QL(&%D:G5S=&UE;G1S("AC;VYS:7-T:6YG(&]F(&YO6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE M'0M86QI9VXZ(&IU2!S96-U28C,30V.W,@ M86)I;&ET>2!T;R!C;VYT:6YU92!A'0M M86QI9VXZ(&IU6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE'0M86QI9VXZ(&IU'0^/'`@6QE M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE'0M86QI9VXZ(&IU6QE/3-$)V9O;G0Z(#$R<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE'0M86QI9VXZ(&IU6QE/3-$)W!A9&1I;F'0M M86QI9VXZ(&-E;G1E6QE/3-$)V9O;G0Z(#$P<'0@5&EM M97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)W9E'0M86QI9VXZ(&-E M;G1E6QE/3-$ M)W9E'0M M86QI9VXZ(&-E;G1E'0M86QI9VXZ M(&-E;G1E6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE6QE/3-$)V)O6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&-E;G1E6QE/3-$)V9O;G0Z M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)W9E6QE/3-$)W=I9'1H.B`R)3L@<&%D M9&EN9RUR:6=H=#H@,"XX<'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\+W1D/@T* M("`@(#QT9"!S='EL93TS1"=W:61T:#H@,3DE.R!P861D:6YG+7)I9VAT.B`P M+CAP=#L@;&EN92UH96EG:'0Z(#$Q-24[('1E>'0M86QI9VXZ(')I9VAT)SX@ M/&9O;G0@6QE/3-$)W=I9'1H.B`R)3L@<&%D9&EN9RUR:6=H=#H@,"XX<'0[(&QI;F4M M:&5I9VAT.B`Q,34E)SX\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@ M,B4[('!A9&1I;F6QE/3-$)W=I9'1H.B`Q-R4[('!A9&1I;F6QE/3-$)W9E M'0M M86QI9VXZ(')I9VAT)SX@/&9O;G0@6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)V9O;G0Z M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)W9EF4Z(#$P<'0G/CPO=&0^ M#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I M;FF4Z(#$P<'0G/CPO=&0^#0H@ M("`@/'1D('-T>6QE/3-$)W!A9&1I;FF4Z(#$R<'0G/CPO M=&0^/"]T'0M M86QI9VXZ(&IU'0^/'`@F$@9F]R('1H92!E>&-L=7-I=F4@;&EC96YS92!T;R!U2!K;F]W+6AO=R!A;F0@:6YF;W)M871I;VX@;F5C M97-S87)Y('1O(&1E=F5L;W`@86YD('-E96L@87!P6QE/3-$)V9O M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE'0M M86QI9VXZ(&IUF$@)FYB6QE/3-$)V9O;G0Z(#$P<'0@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE'0M86QI9VXZ(&IU M6EN9R!V86QU92!O9B!T:&4@87-S971S(&5X8V5E M9',@=&AE:7(@9F%I2P@;W(@82!V86QU92!D971E2!U=&EL:7II;F<@82!D:7-C;W5N=&5D(&-A2P@=V4@;75S="!M M86ME(&%S6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE2<^26X@1F5B'0^/'`@6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE'0M86QI9VXZ(&IU2!I2!W:&]S92!P6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE&ES M=&EN9R!$96UA;F0@3F]T92!A;F0@=&AE(&)A;&%N8V4@;V8@)FYB2XF(S$V,#LF(S$V,#M/;@T*075G=7-T(#,P M+"`R,#$P+"!T:&4@0V]M<&%N>2!H860@96YT97)E9"!I;G1O(&$@9FEN86YC M92!R97!R97-E;G1A=&EO;B!A9W)E96UE;G0@=VET:"!40D2!M87D@8V]N2XF(S$V,#LF(S$V,#M4:&4-"F%D=F%N8V5S('=EFEN M9R!T:&4@;V9F:6-E('-P86-E(&%N9`T*96UP;&]Y965S(&]F(%1"1R!A="!N M;R!C;W-T+CPO<#X-"@T*/'`@6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE2<^ M1F]R('1H92!N:6YE(&%N9"!T:')E92!M;VYT:',@96YD960@2G5N92`S,"P- M"C(P,3$@86YD(#(P,3`L('1H92!#;VUP86YY(&1I9"!N;W0@:6YC=7(@86YY M(&9E97,@=&\@5$)'+CPO<#X-"@T*/'`@6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE'0M86QI M9VXZ(&IU2!B;W)R M;W=E9`T*861D:71I;VYA;"!F=6YD2`F;F)S<#LD-3`V+#`P,"DN)B,Q-C`[)B,Q-C`[5&AE2!A9W)E960@=&\@<&%Y#0IA("9N M8G-P.R0R,#`L,#`P('-U8V-E2!R86ES97,@=&AE(')E;6%I;FEN9R`F;F)S<#LD,RXU(&UI;&QI;VX@8F5I M;F<@;V9F97)E9"!I;B!I=',@8W5R2DN/"]P/CQS<&%N/CPO6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE2<^/&(^075T:&]R:7IE9"!3:&%R97,Z/"]B/CPO<#X-"@T*/'`@ M6QE/3-$)V9O M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2<^/&(^4V5R:65S M($$@0V]N=F5R=&EB;&4@4')E9F5R6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE'!E;G-E2`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`Q,"P-"C(P,3$L('1H92!# M;VUP86YY('-O;&0@-C(S+#0P,"!S:&%R97,@;V8@8V]M;6]N('-T;V-K(&%N M9"!R96-E:79E9"!G'!E;G-E6QE/3-$)V9O;G0Z(#$P M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2<^/&(^5$)'/"]B/CPO<#X-"@T*/'`@6QE/3-$)V9O;G0Z M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE&-H86YG92!F M;W(@86QL(&UO;FEE6QE/3-$)V9O;G0Z(#$P M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE M2!I'0M86QI9VXZ(&IU2X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE'0M86QI9VXZ(&IU M6QE M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE'0M86QI9VXZ(&IU2!A9W)E960@=&\@9&5L:79E<@T*=&\@=&AE($-O;7!A;GD@-"PT,C@L M,S8P('-H87)E2!I M;F-E;G1I=F4@<&QA;B!F;W(-"F1I2`U+"`R,#$Q+CPO<#X-"@T*/'`@6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE2<^/&(^,C`Q,"!);F-E;G1I=F4@4&QA;CH\+V(^/"]P/@T*#0H\<"!S='EL M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)V9O M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2<^3VX@2F%N=6%R>2`V+"`R,#$Q M+"!T:&4@0V]M<&%N>2!A<'!R;W9E9"!T:&4-"FES&5R8VES92!P2!V86QU960@=&AE(&]P=&EO;G,@=71I;&EZ M:6YG(&$@0FQA8VLM4V-H;VQE'!E8W1E9"!V;VQA=&EL:71Y.@T*,C8N,S8E.R!R:7-K+69R964@ M'0M86QI9VXZ(&IU MFEN9R!A($)L86-K+5-C:&]L97,@;W!T M:6]N('!R:6-I;F<@;6]D96P@=VET:"!T:&4@9F]L;&]W:6YG(&%S3H@,C65A'0M M86QI9VXZ(&IU&5R8VES92!O'!E8W1E9"!L:69E(&ES(&1E=&5R;6EN960-"G5S:6YG('1H92`F(S$T M-SMS:6UP;&EF:65D(&UE=&AO9"8C,30X.R!P97)M:71T960@8GD@4W1A9F8@ M06-C;W5N=&EN9R!"=6QL971I;B8C,38P.TYO+B`Q,#2!D:60@;F]T('5S92!T:&4@ M=F]L871I;&ET>2!R871E(&9O2!#;VUM;VX@4W1O8VL-"FAA9"!N;W0@8F5E;B!T6QE/3-$)V9O M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2<^4W1O8VL@8V]M<&5N'0M86QI9VXZ(&IU6QE/3-$)V9O;G0Z(#$P M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2<^26X@2F%N=6%R>2!A;F0@36%R8V@@,C`Q M,2P@=&AE($-O;7!A;GD@:7-S=65D#0HQ+#8W-BPV-C<@=V%R&5R8VES92!P'!I2!V M86QU960@=&AE('=AFEN9R!A($)L86-K+5-C:&]L97,@ M;W!T:6]N('!R:6-I;F<@;6]D96P@=VET:`T*=&AE(&9O;&QO=VEN9R!A3H@,3,N,S4E("T@,C6QE/3-$)V9O;G0Z(#$P<'0@5&EM M97,@3F5W(%)O;6%N+"!4:6UE2<^/&(^)B,Q-C`[/"]B/CPO<#X-"@T*/'`@6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2<^)B,Q-C`[ M/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA M;BP@5&EM97,L(%-E'0M86QI9VXZ(&IUFEN9R!A($)L86-K+5-C:&]L97,@;W!T M:6]N('!R:6-I;F<@;6]D96P@=VET:"!T:&4@9F]L;&]W:6YG(&%S&5R8VES90T*<')I8V4Z("9N8G-P.R0P+C$P("T@)FYB M'!E8W1E9"!T97)M.B`N-2!Y96%R6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE2<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M M86QI9VXZ(&IU'!E8W1E9"!L:69E(&ES('1H92!N=6UB M97(@;V8@>65A&5R8VES92!O'!E8W1E M9"!L:69E(&ES#0ID971E2!D:60@;F]T('5S92!T:&4@=F]L871I;&ET M>2!R871E(&9O6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE2<^/&(^)B,Q-C`[/"]B/CPO<#X-"@T*/'`@6QE/3-$)V9O;G0Z(#$P<'0@5&EM M97,@3F5W(%)O;6%N+"!4:6UE'0M86QI9VXZ(&IU6QE/3-$ M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2<^4'5R2!T:&4@2!S M=6-H(%!U2!H87,@;F]T(&9I;&5D(&%N(&EN:71I86P@2X\+W`^ M#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE'0M86QI9VXZ(&IU&5C=71E9"!I M;B!C;VYN96-T:6]N('=I=&@@=&AE(&-L;W-I;F<-"F]F('1H92!/9F9E6QE/3-$)V9O M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2<^26X@=&AE(&5V96YT('1H92!# M;VUP86YY(&ES('5N86)L92!T;R!F:6QE#0IA(%)E9VES=')A=&EO;B!3=&%T M96UE;G0@8V]V97)I;F<@=&AE(%)E9VES=')A8FQE(%-E8W5R:71I97,@=VET M:&EN(#,P(&1A>7,@9F]L;&]W:6YG('1H92!C;&]S:6YG(&]F('1H92!/9F9E M7,@;V8@:71S(&EN:71I86P@9FEL:6YG(&1A=&4L('1H M96X@87,@;&EQ=6ED871E9`T*9&%M86=E2!W:6QL(&=R M86YT(&5A8V@@2`Q,"P@,C`Q,2X@5&AE($-O;7!A;GD@:&%D(&YO="!F:6QE9"!A(')E M9VES=')A=&EO;B!S=&%T96UE;G0-"F%S(')E<75I6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE'0M86QI9VXZ(&IU6UE;G0@86=R M965M96YT.CPO<#X-"@T*/'`@6QE/3-$)V9O;G0Z(#$P M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2<^37(N($AA9'-A;&P@=VEL;"!S97)V92!A M2!O M9B`F;F)S<#LD,3(P+#`P,"!F;W(@=&AE(&9I6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE M6QE/3-$)V9O;G0Z(#$P<'0@5&EM M97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$R<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE2<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)V9O;G0Z(#$P<'0@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE65A2!O=7(@8F]A2!O=7(@8F]A6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE6UE;G0@=VET:"!O=7(@8V]M<&%N>2!P=7)S=6%N="!T;R!H:7,@16UP;&]Y M;65N="!!9W)E96UE;G0@=V%S('1E'0M86QI M9VXZ(&IU2!T M:&4@)B,Q-#<[4&QA:6YT:69F2!R96QI968@9G)O;2!C97)T86EN(&%L;&5G871I M;VYS($UR+B!#;VYN96QL(&AA6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2<^)B,Q-C`[ M/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA M;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU"!.;RX@,3`S,#`W+S$Q*2!A9V%I;G-T($UR+B!- M8T-O>2P@=&AE($-O;7!A;GDL($IO28C,30V.W,@6QE/3-$)V9O;G0Z(#$P<'0@5&EM M97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE